CN104169258B - 用作激酶活性调节剂的新颖的杂环羧酰胺 - Google Patents
用作激酶活性调节剂的新颖的杂环羧酰胺 Download PDFInfo
- Publication number
- CN104169258B CN104169258B CN201280063286.7A CN201280063286A CN104169258B CN 104169258 B CN104169258 B CN 104169258B CN 201280063286 A CN201280063286 A CN 201280063286A CN 104169258 B CN104169258 B CN 104169258B
- Authority
- CN
- China
- Prior art keywords
- carboxylic acid
- phenyl
- quinazoline
- amino
- hal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 heterocyclic carboxamide Chemical class 0.000 title claims abstract description 152
- 230000000694 effects Effects 0.000 title description 13
- 108091000080 Phosphotransferase Proteins 0.000 title description 9
- 102000020233 phosphotransferase Human genes 0.000 title description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 134
- 201000010099 disease Diseases 0.000 claims abstract description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 24
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 230000002062 proliferating effect Effects 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 246
- 150000003839 salts Chemical class 0.000 claims description 65
- 108091008611 Protein Kinase B Proteins 0.000 claims description 56
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 49
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 35
- GYBHRTQLUQOYID-UHFFFAOYSA-N quinazoline-8-carboxamide Chemical class N1=CN=C2C(C(=O)N)=CC=CC2=C1 GYBHRTQLUQOYID-UHFFFAOYSA-N 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- CJPHZAYAIMRXDX-UHFFFAOYSA-N 4-(3-chloro-4-fluorophenyl)piperidine Chemical class C1=C(Cl)C(F)=CC=C1C1CCNCC1 CJPHZAYAIMRXDX-UHFFFAOYSA-N 0.000 claims description 2
- NHHCYBVEYCSVEN-UHFFFAOYSA-N 4-(4-chloro-3-fluorophenyl)piperidine Chemical class C1=C(Cl)C(F)=CC(C2CCNCC2)=C1 NHHCYBVEYCSVEN-UHFFFAOYSA-N 0.000 claims description 2
- AFYALJSDFPSAAZ-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidine Chemical class C1=CC(F)=CC=C1C1CCNCC1 AFYALJSDFPSAAZ-UHFFFAOYSA-N 0.000 claims description 2
- GVAMKXJAXZYEAW-UHFFFAOYSA-N 4-[3-fluoro-4-(trifluoromethyl)phenyl]piperidine Chemical class C1=C(C(F)(F)F)C(F)=CC(C2CCNCC2)=C1 GVAMKXJAXZYEAW-UHFFFAOYSA-N 0.000 claims description 2
- SFFJZCPGYSFVNX-UHFFFAOYSA-N 5-[[4-[3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]amino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC1CNCC1C1=CC=CC(C(F)(F)F)=C1 SFFJZCPGYSFVNX-UHFFFAOYSA-N 0.000 claims description 2
- ZIRLUWNUUJIIGT-UHFFFAOYSA-N 5-[[4-[4-(trifluoromethoxy)phenyl]pyrrolidin-3-yl]amino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC1CNCC1C1=CC=C(OC(F)(F)F)C=C1 ZIRLUWNUUJIIGT-UHFFFAOYSA-N 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 136
- 239000002585 base Substances 0.000 description 110
- 239000000203 mixture Substances 0.000 description 98
- 238000005859 coupling reaction Methods 0.000 description 86
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 80
- 239000000543 intermediate Substances 0.000 description 79
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 73
- 239000000243 solution Substances 0.000 description 72
- 150000002825 nitriles Chemical class 0.000 description 71
- 238000000034 method Methods 0.000 description 70
- 239000000376 reactant Substances 0.000 description 57
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 45
- JSWVSPDINVTLGF-UHFFFAOYSA-N 5-bromoquinazoline-8-carbonitrile Chemical compound C1=NC=C2C(Br)=CC=C(C#N)C2=N1 JSWVSPDINVTLGF-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 239000012141 concentrate Substances 0.000 description 31
- 235000008504 concentrate Nutrition 0.000 description 31
- 230000008569 process Effects 0.000 description 31
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 29
- 239000012043 crude product Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 22
- 239000007787 solid Chemical class 0.000 description 22
- 150000001412 amines Chemical class 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 17
- 229940002612 prodrug Drugs 0.000 description 17
- 239000012453 solvate Substances 0.000 description 17
- 238000005406 washing Methods 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- 241000124008 Mammalia Species 0.000 description 13
- 102000001253 Protein Kinase Human genes 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 108060006633 protein kinase Proteins 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000010511 deprotection reaction Methods 0.000 description 12
- 239000003480 eluent Substances 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- HPQRQAOVNXWEEQ-UHFFFAOYSA-N quinoline-8-carboxamide Chemical class C1=CN=C2C(C(=O)N)=CC=CC2=C1 HPQRQAOVNXWEEQ-UHFFFAOYSA-N 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 150000004702 methyl esters Chemical class 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000003513 alkali Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004296 chiral HPLC Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 239000001117 sulphuric acid Substances 0.000 description 6
- 235000011149 sulphuric acid Nutrition 0.000 description 6
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 5
- 0 CC(C(C1)C1*1C#*)C1=C Chemical compound CC(C(C1)C1*1C#*)C1=C 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 5
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- BZCGWAXQDLXLQM-UHFFFAOYSA-N phosphoryl trichloride Chemical group ClP(Cl)(Cl)=O.ClP(Cl)(Cl)=O BZCGWAXQDLXLQM-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 4
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 125000005997 bromomethyl group Chemical group 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000000068 chlorophenyl group Chemical group 0.000 description 4
- 238000003821 enantio-separation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 150000003053 piperidines Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- VQEFEANMTJWGPR-SNAWJCMRSA-N 1-[(e)-2-nitroethenyl]-3-(trifluoromethoxy)benzene Chemical compound [O-][N+](=O)\C=C\C1=CC=CC(OC(F)(F)F)=C1 VQEFEANMTJWGPR-SNAWJCMRSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000002278 Ribosomal Proteins Human genes 0.000 description 3
- 108010000605 Ribosomal Proteins Proteins 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 210000004247 hand Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- IHRLTIQTMTVDGZ-UHFFFAOYSA-N methyl 5-bromoquinoline-8-carboxylate Chemical compound C1=CN=C2C(C(=O)OC)=CC=C(Br)C2=C1 IHRLTIQTMTVDGZ-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 3
- OMRRMLNZFJXOTG-UHFFFAOYSA-N n-phenylpiperidine-3-carboxamide Chemical class C1CCNCC1C(=O)NC1=CC=CC=C1 OMRRMLNZFJXOTG-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- KIFCSMQTGWVMOD-UHFFFAOYSA-N 1-(3-fluorophenyl)piperazine Chemical compound FC1=CC=CC(N2CCNCC2)=C1 KIFCSMQTGWVMOD-UHFFFAOYSA-N 0.000 description 2
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- LPHFYCBXDGGXRD-UHFFFAOYSA-N 4-(2-trimethylsilylethoxycarbonylamino)pyrrolidine-1,3-dicarboxylic acid Chemical class C[Si](C)(C)CCOC(=O)NC1CN(C(O)=O)CC1C(O)=O LPHFYCBXDGGXRD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IPKSNWXGEIHOMR-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]piperidine Chemical class FC(F)(F)C1=CC=CC(C2CCNCC2)=C1 IPKSNWXGEIHOMR-UHFFFAOYSA-N 0.000 description 2
- QDHSTXGSUUWPSN-UHFFFAOYSA-N 4-phenylpiperidin-3-amine Chemical class NC1CNCCC1C1=CC=CC=C1 QDHSTXGSUUWPSN-UHFFFAOYSA-N 0.000 description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- FZZVRYSDVQBFMK-UHFFFAOYSA-N 5-[3-[[(2,4-difluorobenzoyl)amino]methyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical compound C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CNC(=O)C1=CC=C(F)C=C1F FZZVRYSDVQBFMK-UHFFFAOYSA-N 0.000 description 2
- JMUHLJWQJXFIJZ-HSZRJFAPSA-N 5-[[(1s)-1-(3-fluorophenyl)-2-[methyl-(4-nitrophenyl)sulfonylamino]ethyl]amino]quinoline-8-carboxamide Chemical class C1([C@H](NC=2C3=CC=CN=C3C(C(N)=O)=CC=2)CN(C)S(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=CC(F)=C1 JMUHLJWQJXFIJZ-HSZRJFAPSA-N 0.000 description 2
- RFPUAYMRJMGCAD-UHFFFAOYSA-N 5-[[4-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-yl]amino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NC1CNCC1C1=CC=CC(OC(F)(F)F)=C1 RFPUAYMRJMGCAD-UHFFFAOYSA-N 0.000 description 2
- REIFWJGDIKRUSB-UHFFFAOYSA-N 5-bromo-8-methylquinoline Chemical compound C1=CN=C2C(C)=CC=C(Br)C2=C1 REIFWJGDIKRUSB-UHFFFAOYSA-N 0.000 description 2
- CHODTZCXWXCALP-UHFFFAOYSA-N 5-bromoquinoline Chemical compound C1=CC=C2C(Br)=CC=CC2=N1 CHODTZCXWXCALP-UHFFFAOYSA-N 0.000 description 2
- DAYKHFAZOORREQ-UHFFFAOYSA-N 5-bromoquinoline-8-carbonitrile Chemical compound C1=CC=C2C(Br)=CC=C(C#N)C2=N1 DAYKHFAZOORREQ-UHFFFAOYSA-N 0.000 description 2
- SMDUUZMMJKRMDS-UHFFFAOYSA-N 5-bromoquinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=C(Br)C2=C1 SMDUUZMMJKRMDS-UHFFFAOYSA-N 0.000 description 2
- GZRXSFZDLGKFLN-UHFFFAOYSA-N 8-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C(C)=CC=C2 GZRXSFZDLGKFLN-UHFFFAOYSA-N 0.000 description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical compound C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YKZDSVHVOYVKBV-UHFFFAOYSA-N N-[(5-bromoquinazolin-8-yl)methylidene]hydroxylamine Chemical compound ON=Cc1ccc(Br)c2cncnc12 YKZDSVHVOYVKBV-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- ODLMAHJVESYWTB-UHFFFAOYSA-N ethylmethylbenzene Natural products CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- QQGBVEVFLBEWKI-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]pyrrolidin-3-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC1CNCC1 QQGBVEVFLBEWKI-UHFFFAOYSA-N 0.000 description 2
- SASNBVQSOZSTPD-UHFFFAOYSA-N n-methylphenethylamine Chemical compound CNCCC1=CC=CC=C1 SASNBVQSOZSTPD-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- CIIFKVFOVFJZDM-UHFFFAOYSA-N quinoline-8-carbonitrile Chemical compound C1=CN=C2C(C#N)=CC=CC2=C1 CIIFKVFOVFJZDM-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- IQAHBRRDEKSXCZ-UHFFFAOYSA-N tert-butyl 3-[(3,4-dichlorophenyl)methylamino]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C1)NCc1ccc(Cl)c(Cl)c1 IQAHBRRDEKSXCZ-UHFFFAOYSA-N 0.000 description 2
- DTEJPZAKLVEJFR-UHFFFAOYSA-N tert-butyl 3-amino-4-[(3-fluorophenyl)carbamoyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(N)C1C(=O)NC1=CC=CC(F)=C1 DTEJPZAKLVEJFR-UHFFFAOYSA-N 0.000 description 2
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- RQYKQWFHJOBBAO-JTQLQIEISA-N (2s)-1-benzoylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)C1=CC=CC=C1 RQYKQWFHJOBBAO-JTQLQIEISA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- ZYMCBJWUWHHVRX-UHFFFAOYSA-N (4-nitrophenyl)-phenylmethanone Chemical group C1=CC([N+](=O)[O-])=CC=C1C(=O)C1=CC=CC=C1 ZYMCBJWUWHHVRX-UHFFFAOYSA-N 0.000 description 1
- JDAQDIQHICLYKH-PZORYLMUSA-N (4s)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylpyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)C[C@@H]1C1=CC=CC=C1 JDAQDIQHICLYKH-PZORYLMUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical class CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical class C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 150000000177 1,2,3-triazoles Chemical class 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- WICKLEOONJPMEQ-UHFFFAOYSA-N 1-(2-methylphenyl)piperazine Chemical compound CC1=CC=CC=C1N1CCNCC1 WICKLEOONJPMEQ-UHFFFAOYSA-N 0.000 description 1
- OGLZSMPGMUDNKR-UHFFFAOYSA-N 1-(2-methylphenyl)piperidine Chemical class CC1=CC=CC=C1N1CCCCC1 OGLZSMPGMUDNKR-UHFFFAOYSA-N 0.000 description 1
- VRVIKRZIQWEYFB-UHFFFAOYSA-N 1-(3,4-difluorophenyl)piperazine Chemical compound C1=C(F)C(F)=CC=C1N1CCNCC1 VRVIKRZIQWEYFB-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- GBOWGKOVMBDPJF-UHFFFAOYSA-N 1-fluoro-3-(trifluoromethyl)benzene Chemical compound FC1=CC=CC(C(F)(F)F)=C1 GBOWGKOVMBDPJF-UHFFFAOYSA-N 0.000 description 1
- UNHOPMIDKWXFMF-UHFFFAOYSA-N 1-methylpyrrolidin-3-amine Chemical compound CN1CCC(N)C1 UNHOPMIDKWXFMF-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 1
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- DVBCPSHJMOREDA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-pyrrolidin-3-ylacetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1CNCC1 DVBCPSHJMOREDA-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- OOKSMYZBWRKRGU-UHFFFAOYSA-N 2-benzoyl-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)C(=O)C1=CC=CC=C1 OOKSMYZBWRKRGU-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- QVGYLPDGEMYDSL-UHFFFAOYSA-N 2-nitro-1-[3-(trifluoromethoxy)phenyl]ethanol Chemical compound [O-][N+](=O)CC(O)C1=CC=CC(OC(F)(F)F)=C1 QVGYLPDGEMYDSL-UHFFFAOYSA-N 0.000 description 1
- DXLHNFXYCUGDNF-UHFFFAOYSA-N 2-phenyl-n-pyrrolidin-3-ylacetamide Chemical compound C1CNCC1NC(=O)CC1=CC=CC=C1 DXLHNFXYCUGDNF-UHFFFAOYSA-N 0.000 description 1
- RIMRLBGNCLMSNH-UHFFFAOYSA-N 2-phenylpiperazine Chemical compound C1NCCNC1C1=CC=CC=C1 RIMRLBGNCLMSNH-UHFFFAOYSA-N 0.000 description 1
- MPCXCKXGCBIQNZ-UHFFFAOYSA-N 2-piperazin-1-yl-2-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(CN)N1CCNCC1 MPCXCKXGCBIQNZ-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- GLZRMVTXAKDQMC-UHFFFAOYSA-N 3-(2-phenylethyl)pyrrolidine Chemical compound C1CNCC1CCC1=CC=CC=C1 GLZRMVTXAKDQMC-UHFFFAOYSA-N 0.000 description 1
- XQSCARJMOSCJRY-UHFFFAOYSA-N 3-(phenylmethoxycarbonylaminomethyl)pyrrolidine-3-carboxylic acid hydrochloride Chemical compound Cl.OC(=O)C1(CNC(=O)OCc2ccccc2)CCNC1 XQSCARJMOSCJRY-UHFFFAOYSA-N 0.000 description 1
- NONFLFDSOSZQHR-UHFFFAOYSA-N 3-(trimethylsilyl)propionic acid Chemical compound C[Si](C)(C)CCC(O)=O NONFLFDSOSZQHR-UHFFFAOYSA-N 0.000 description 1
- AEJQCFVWSVSHEF-UHFFFAOYSA-N 3-amino-n-(3,4-difluorophenyl)pyrrolidine-3-carboxamide Chemical class C=1C=C(F)C(F)=CC=1NC(=O)C1(N)CCNC1 AEJQCFVWSVSHEF-UHFFFAOYSA-N 0.000 description 1
- FKRDSSFDGLFPDE-UHFFFAOYSA-N 3-amino-n-(3-fluorophenyl)pyrrolidine-3-carboxamide Chemical class C=1C=CC(F)=CC=1NC(=O)C1(N)CCNC1 FKRDSSFDGLFPDE-UHFFFAOYSA-N 0.000 description 1
- CHTURIQPIFJVDZ-UHFFFAOYSA-N 3-amino-n-(4-fluorophenyl)pyrrolidine-3-carboxamide Chemical class C=1C=C(F)C=CC=1NC(=O)C1(N)CCNC1 CHTURIQPIFJVDZ-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- WFGYSQDPURFIFL-UHFFFAOYSA-N 3-chloro-n-methylaniline Chemical compound CNC1=CC=CC(Cl)=C1 WFGYSQDPURFIFL-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- AFQYBBFSDHKQJV-UHFFFAOYSA-N 3-phenylpyrrolidin-3-ol Chemical compound C=1C=CC=CC=1C1(O)CCNC1 AFQYBBFSDHKQJV-UHFFFAOYSA-N 0.000 description 1
- PRRFFTYUBPGHLE-UHFFFAOYSA-N 3-phenylpyrrolidine Chemical compound C1NCCC1C1=CC=CC=C1 PRRFFTYUBPGHLE-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HISJUCXTBJGMGD-UHFFFAOYSA-N 4-(2-methylphenyl)piperidin-3-amine Chemical class CC1=CC=CC=C1C1C(N)CNCC1 HISJUCXTBJGMGD-UHFFFAOYSA-N 0.000 description 1
- ICRCMOXGEJQDSX-UHFFFAOYSA-N 4-(2-methylphenyl)piperidine Chemical class CC1=CC=CC=C1C1CCNCC1 ICRCMOXGEJQDSX-UHFFFAOYSA-N 0.000 description 1
- BCYGJJOHAFKLLF-UHFFFAOYSA-N 4-(3-fluorophenyl)piperidine Chemical class FC1=CC=CC(C2CCNCC2)=C1 BCYGJJOHAFKLLF-UHFFFAOYSA-N 0.000 description 1
- AKGAUMQWPLQYHW-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]piperidine Chemical class C1=CC(C(F)(F)F)=CC=C1C1CCNCC1 AKGAUMQWPLQYHW-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- UTBDPFFXKANFFT-UHFFFAOYSA-N 4-chloro-8-methylquinazoline Chemical compound N1=CN=C2C(C)=CC=CC2=C1Cl UTBDPFFXKANFFT-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GOIIQXABHXILGU-UHFFFAOYSA-N 5-(3-phenylpropylamino)quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCCCC1=CC=CC=C1 GOIIQXABHXILGU-UHFFFAOYSA-N 0.000 description 1
- DJODPWAPMOLBHC-UHFFFAOYSA-N 5-(4-phenylbutylamino)quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCCCCC1=CC=CC=C1 DJODPWAPMOLBHC-UHFFFAOYSA-N 0.000 description 1
- XCDUPGWCPCEMHW-UHFFFAOYSA-N 5-(benzylamino)quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC=C1 XCDUPGWCPCEMHW-UHFFFAOYSA-N 0.000 description 1
- ZBCZYSYUCXKPFW-UHFFFAOYSA-N 5-(benzylamino)quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC=C1 ZBCZYSYUCXKPFW-UHFFFAOYSA-N 0.000 description 1
- HRPLAOCUGOORSU-UHFFFAOYSA-N 5-(pyridin-3-ylmethylamino)quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CN=C1 HRPLAOCUGOORSU-UHFFFAOYSA-N 0.000 description 1
- IGKUODKWOYVWNS-UHFFFAOYSA-N 5-[(1-methylpyrrolidin-3-yl)amino]quinazoline-8-carboxamide Chemical class C1N(C)CCC1NC1=CC=C(C(N)=O)C2=NC=NC=C12 IGKUODKWOYVWNS-UHFFFAOYSA-N 0.000 description 1
- YYITUEFJLGJEJJ-UHFFFAOYSA-N 5-[(2-amino-2-phenylacetyl)amino]quinoline-8-carboxamide Chemical class C=1C=C(C(N)=O)C2=NC=CC=C2C=1NC(=O)C(N)C1=CC=CC=C1 YYITUEFJLGJEJJ-UHFFFAOYSA-N 0.000 description 1
- QTCOHIBUNSAYAM-UHFFFAOYSA-N 5-[(2-fluorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC=C1F QTCOHIBUNSAYAM-UHFFFAOYSA-N 0.000 description 1
- UCAJSXGLVIYERD-UHFFFAOYSA-N 5-[(3,4,5-trifluorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC(F)=C(F)C(F)=C1 UCAJSXGLVIYERD-UHFFFAOYSA-N 0.000 description 1
- ZVFFUWYNLKHQIZ-UHFFFAOYSA-N 5-[(3,4-difluorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=C(F)C(F)=C1 ZVFFUWYNLKHQIZ-UHFFFAOYSA-N 0.000 description 1
- WSEAJWAXWQGKPA-UHFFFAOYSA-N 5-[(3-chlorophenyl)methylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC(Cl)=C1 WSEAJWAXWQGKPA-UHFFFAOYSA-N 0.000 description 1
- JDJMGHRRPUDVSU-UHFFFAOYSA-N 5-[(3-chlorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC(Cl)=C1 JDJMGHRRPUDVSU-UHFFFAOYSA-N 0.000 description 1
- GKVSBZBLRXELAM-UHFFFAOYSA-N 5-[(3-fluorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=CC(F)=C1 GKVSBZBLRXELAM-UHFFFAOYSA-N 0.000 description 1
- WUEUOVQNIFRQHZ-HXUWFJFHSA-N 5-[(3r)-3-amino-3-(phenylcarbamoyl)pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class O=C([C@@]1(N)CCN(C1)C1=CC=C(C2=NC=NC=C21)C(=O)N)NC1=CC=CC=C1 WUEUOVQNIFRQHZ-HXUWFJFHSA-N 0.000 description 1
- VISYXENNOBZZBT-PBHICJAKSA-N 5-[(3r,4r)-3-amino-4-(3-fluorophenyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical compound C1([C@H]2CCN(C[C@@H]2N)C=2C3=CN=CN=C3C(C(N)=O)=CC=2)=CC=CC(F)=C1 VISYXENNOBZZBT-PBHICJAKSA-N 0.000 description 1
- ISSHDEMQWJANGA-PBHICJAKSA-N 5-[(3r,4r)-3-amino-4-(4-fluorophenyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical compound C1([C@H]2CCN(C[C@@H]2N)C=2C3=CN=CN=C3C(C(N)=O)=CC=2)=CC=C(F)C=C1 ISSHDEMQWJANGA-PBHICJAKSA-N 0.000 description 1
- WUEUOVQNIFRQHZ-FQEVSTJZSA-N 5-[(3s)-3-amino-3-(phenylcarbamoyl)pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class O=C([C@]1(N)CCN(C1)C1=CC=C(C2=NC=NC=C21)C(=O)N)NC1=CC=CC=C1 WUEUOVQNIFRQHZ-FQEVSTJZSA-N 0.000 description 1
- VISYXENNOBZZBT-RHSMWYFYSA-N 5-[(3s,4r)-3-amino-4-(3-fluorophenyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical compound C1([C@H]2CCN(C[C@H]2N)C=2C3=CN=CN=C3C(C(N)=O)=CC=2)=CC=CC(F)=C1 VISYXENNOBZZBT-RHSMWYFYSA-N 0.000 description 1
- ISSHDEMQWJANGA-RHSMWYFYSA-N 5-[(3s,4r)-3-amino-4-(4-fluorophenyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical compound C1([C@H]2CCN(C[C@H]2N)C=2C3=CN=CN=C3C(C(N)=O)=CC=2)=CC=C(F)C=C1 ISSHDEMQWJANGA-RHSMWYFYSA-N 0.000 description 1
- FBEHHQVDNWZHMS-UHFFFAOYSA-N 5-[(4-fluorophenyl)methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=C(F)C=C1 FBEHHQVDNWZHMS-UHFFFAOYSA-N 0.000 description 1
- JFNFEXHHIFLGCI-UHFFFAOYSA-N 5-[2-(3,4-difluorophenyl)ethylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCCC1=CC=C(F)C(F)=C1 JFNFEXHHIFLGCI-UHFFFAOYSA-N 0.000 description 1
- FODVSAUJMGFYEF-UHFFFAOYSA-N 5-[2-(3-fluorophenyl)ethylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCCC1=CC=CC(F)=C1 FODVSAUJMGFYEF-UHFFFAOYSA-N 0.000 description 1
- AGDNLBHROLOTDM-UHFFFAOYSA-N 5-[2-(4-fluorophenyl)ethylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCCC1=CC=C(F)C=C1 AGDNLBHROLOTDM-UHFFFAOYSA-N 0.000 description 1
- QJDCIKHAJGVEOZ-QGZVFWFLSA-N 5-[2-phenylethyl-[(3R)-piperidin-3-yl]amino]quinazoline-8-carboxamide Chemical class NC(=O)c1ccc(N(CCc2ccccc2)[C@@H]2CCCNC2)c2cncnc12 QJDCIKHAJGVEOZ-QGZVFWFLSA-N 0.000 description 1
- UMRPTDGLNAANGL-UHFFFAOYSA-N 5-[3-(2-phenylethyl)pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CCC1=CC=CC=C1 UMRPTDGLNAANGL-UHFFFAOYSA-N 0.000 description 1
- BPJGWADXXYQSHV-UHFFFAOYSA-N 5-[3-(aminomethyl)-3-(phenylcarbamoyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical class C1CCN(C=2C3=CN=CN=C3C(C(N)=O)=CC=2)CC1(CN)C(=O)NC1=CC=CC=C1 BPJGWADXXYQSHV-UHFFFAOYSA-N 0.000 description 1
- RCLJQVCJIGNUQX-UHFFFAOYSA-N 5-[3-(aminomethyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical class C1C(CN)CCCN1C1=CC=C(C(N)=O)C2=NC=NC=C12 RCLJQVCJIGNUQX-UHFFFAOYSA-N 0.000 description 1
- PLBMNGOXGSUIFL-UHFFFAOYSA-N 5-[3-(methylaminomethyl)piperidin-1-yl]quinazoline-8-carboxamide Chemical class C1C(CNC)CCCN1C1=CC=C(C(N)=O)C2=NC=NC=C12 PLBMNGOXGSUIFL-UHFFFAOYSA-N 0.000 description 1
- PDVFGRQBHKQZEN-UHFFFAOYSA-N 5-[3-[(2-phenylacetyl)amino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1NC(=O)CC1=CC=CC=C1 PDVFGRQBHKQZEN-UHFFFAOYSA-N 0.000 description 1
- CGOZFXOCALCDCR-UHFFFAOYSA-N 5-[3-[(3,4-dichlorophenyl)methyl-methylamino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C1CN(C=2C3=CN=CN=C3C(C(N)=O)=CC=2)CC1N(C)CC1=CC=C(Cl)C(Cl)=C1 CGOZFXOCALCDCR-UHFFFAOYSA-N 0.000 description 1
- BNXVNBDORNIMJY-UHFFFAOYSA-N 5-[3-[(3,4-dichlorophenyl)methylamino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1NCC1=CC=C(Cl)C(Cl)=C1 BNXVNBDORNIMJY-UHFFFAOYSA-N 0.000 description 1
- DLUGKDOSIIJDOJ-UHFFFAOYSA-N 5-[3-[(3,4-difluorobenzoyl)amino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1NC(=O)C1=CC=C(F)C(F)=C1 DLUGKDOSIIJDOJ-UHFFFAOYSA-N 0.000 description 1
- JHBCCRWTWRWFJI-UHFFFAOYSA-N 5-[3-[[(2,5-difluorobenzoyl)amino]methyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CNC(=O)C1=CC(F)=CC=C1F JHBCCRWTWRWFJI-UHFFFAOYSA-N 0.000 description 1
- GPHJWJNDSJUYFY-UHFFFAOYSA-N 5-[3-[[(3,4-difluorobenzoyl)amino]methyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CNC(=O)C1=CC=C(F)C(F)=C1 GPHJWJNDSJUYFY-UHFFFAOYSA-N 0.000 description 1
- LWDJBMITBMJKLQ-UHFFFAOYSA-N 5-[3-[[2-(4-fluorophenyl)acetyl]amino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1NC(=O)CC1=CC=C(F)C=C1 LWDJBMITBMJKLQ-UHFFFAOYSA-N 0.000 description 1
- MSTMCABMBBYBGR-UHFFFAOYSA-N 5-[3-[[3-(trifluoromethyl)benzoyl]amino]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1NC(=O)C1=CC=CC(C(F)(F)F)=C1 MSTMCABMBBYBGR-UHFFFAOYSA-N 0.000 description 1
- FKFOFKDXALAKRG-UHFFFAOYSA-N 5-[3-[[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]methyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CNC(=O)C1=CC=C(C(F)(F)F)C=C1F FKFOFKDXALAKRG-UHFFFAOYSA-N 0.000 description 1
- JVQXDDDNXJYPCG-UHFFFAOYSA-N 5-[3-[[[3-(trifluoromethyl)benzoyl]amino]methyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical compound C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1CNC(=O)C1=CC=CC(C(F)(F)F)=C1 JVQXDDDNXJYPCG-UHFFFAOYSA-N 0.000 description 1
- JQAYIDUGXAEGLA-UHFFFAOYSA-N 5-[3-[benzyl-[2-(dimethylamino)ethyl]carbamoyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C1CN(C=2C3=CN=CN=C3C(C(N)=O)=CC=2)CC1C(=O)N(CCN(C)C)CC1=CC=CC=C1 JQAYIDUGXAEGLA-UHFFFAOYSA-N 0.000 description 1
- WUEUOVQNIFRQHZ-UHFFFAOYSA-N 5-[3-amino-3-(phenylcarbamoyl)pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1(N)C(=O)NC1=CC=CC=C1 WUEUOVQNIFRQHZ-UHFFFAOYSA-N 0.000 description 1
- YXBOJAMTAFEUDC-UHFFFAOYSA-N 5-[3-amino-3-[(3,4-difluorophenyl)carbamoyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1(N)C(=O)NC1=CC=C(F)C(F)=C1 YXBOJAMTAFEUDC-UHFFFAOYSA-N 0.000 description 1
- XGDOTBLDLALKSZ-UHFFFAOYSA-N 5-[3-amino-3-[[4-fluoro-3-(trifluoromethyl)phenyl]carbamoyl]pyrrolidin-1-yl]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1N(C1)CCC1(N)C(=O)NC1=CC=C(F)C(C(F)(F)F)=C1 XGDOTBLDLALKSZ-UHFFFAOYSA-N 0.000 description 1
- SXQNITDIMFZZKR-UHFFFAOYSA-N 5-[3-amino-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]quinazoline-8-carboxamide Chemical compound NC1CN(C=2C3=CN=CN=C3C(C(N)=O)=CC=2)CCC1C1=CC=CC(C(F)(F)F)=C1 SXQNITDIMFZZKR-UHFFFAOYSA-N 0.000 description 1
- HTHGGNVIOAHWKI-UHFFFAOYSA-N 5-[3-amino-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]quinazoline-8-carboxamide Chemical class NC1CN(C=2C3=CN=CN=C3C(C(N)=O)=CC=2)CCC1C1=CC=C(C(F)(F)F)C=C1 HTHGGNVIOAHWKI-UHFFFAOYSA-N 0.000 description 1
- UBWQDRPUCAXDSY-MRXNPFEDSA-N 5-[[(1s)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino]quinazoline-8-carboxamide Chemical class C1([C@H](NC=2C3=CN=CN=C3C(C(N)=O)=CC=2)CNC)=CC=CC(F)=C1 UBWQDRPUCAXDSY-MRXNPFEDSA-N 0.000 description 1
- TZZFEMJKXZWNDY-QGZVFWFLSA-N 5-[[(1s)-1-(3-fluorophenyl)-2-(methylamino)ethyl]amino]quinoline-8-carboxamide Chemical class C1([C@H](NC=2C3=CC=CN=C3C(C(N)=O)=CC=2)CNC)=CC=CC(F)=C1 TZZFEMJKXZWNDY-QGZVFWFLSA-N 0.000 description 1
- QUMYRYSCDCPFNX-SECBINFHSA-N 5-[[(3r)-pyrrolidin-3-yl]methylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC[C@@H]1CCNC1 QUMYRYSCDCPFNX-SECBINFHSA-N 0.000 description 1
- QUMYRYSCDCPFNX-VIFPVBQESA-N 5-[[(3s)-pyrrolidin-3-yl]methylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC[C@H]1CCNC1 QUMYRYSCDCPFNX-VIFPVBQESA-N 0.000 description 1
- RFPUAYMRJMGCAD-FUHWJXTLSA-N 5-[[(3s,4r)-4-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-yl]amino]quinoline-8-carboxamide Chemical compound C1([C@@H]2CNC[C@H]2NC2=CC=C(C3=NC=CC=C32)C(=O)N)=CC=CC(OC(F)(F)F)=C1 RFPUAYMRJMGCAD-FUHWJXTLSA-N 0.000 description 1
- XBZDVWWKOJXBIB-ATNAJCNCSA-N 5-[[(4r)-4-(3-chloro-5-fluorophenyl)pyrrolidin-3-yl]amino]quinoline-8-carboxamide Chemical class C1([C@@H]2CNCC2NC2=CC=C(C3=NC=CC=C32)C(=O)N)=CC(F)=CC(Cl)=C1 XBZDVWWKOJXBIB-ATNAJCNCSA-N 0.000 description 1
- ZPPZCXJBRXNTAK-TZHYSIJRSA-N 5-[[(4s)-4-(3-fluorophenyl)pyrrolidine-3-carbonyl]amino]quinoline-8-carboxamide Chemical class C1([C@H]2CNCC2C(=O)NC2=CC=C(C3=NC=CC=C32)C(=O)N)=CC=CC(F)=C1 ZPPZCXJBRXNTAK-TZHYSIJRSA-N 0.000 description 1
- ORCHNWVAWGAOCS-IKJXHCRLSA-N 5-[[(4s)-4-phenylpyrrolidine-2-carbonyl]amino]quinoline-8-carboxamide Chemical class C1([C@@H]2CC(NC2)C(=O)NC2=CC=C(C3=NC=CC=C32)C(=O)N)=CC=CC=C1 ORCHNWVAWGAOCS-IKJXHCRLSA-N 0.000 description 1
- BTLXOEZIMXLEQI-UHFFFAOYSA-N 5-[[2-(3-chlorophenyl)-2-(dimethylamino)ethyl]amino]quinazoline-8-carboxamide Chemical class C=1C=C(C(N)=O)C2=NC=NC=C2C=1NCC(N(C)C)C1=CC=CC(Cl)=C1 BTLXOEZIMXLEQI-UHFFFAOYSA-N 0.000 description 1
- SCWYHQWISDGCJM-UHFFFAOYSA-N 5-[[3-(4-fluorophenyl)piperidin-4-yl]amino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC1CCNCC1C1=CC=C(F)C=C1 SCWYHQWISDGCJM-UHFFFAOYSA-N 0.000 description 1
- UAJOXFXDZJBOGE-UHFFFAOYSA-N 5-[[3-(phenylcarbamoyl)pyrrolidin-3-yl]methylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCC1(C(=O)NC=2C=CC=CC=2)CCNC1 UAJOXFXDZJBOGE-UHFFFAOYSA-N 0.000 description 1
- STHYEXZXVZBDIN-UHFFFAOYSA-N 5-[[3-(phenylcarbamoyl)pyrrolidin-3-yl]methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1(C(=O)NC=2C=CC=CC=2)CCNC1 STHYEXZXVZBDIN-UHFFFAOYSA-N 0.000 description 1
- ARDCHIOWMUVWOX-UHFFFAOYSA-N 5-[[4-(3-chloro-5-fluorophenyl)pyrrolidin-3-yl]amino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC1CNCC1C1=CC(F)=CC(Cl)=C1 ARDCHIOWMUVWOX-UHFFFAOYSA-N 0.000 description 1
- DVGKVATVEFWTFI-UHFFFAOYSA-N 5-[[4-(phenylcarbamoyl)piperidin-4-yl]methylamino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NCC1(C(=O)NC=2C=CC=CC=2)CCNCC1 DVGKVATVEFWTFI-UHFFFAOYSA-N 0.000 description 1
- KEKMTFSRYLVCEZ-UHFFFAOYSA-N 5-[[4-[3-(trifluoromethoxy)phenyl]pyrrolidin-3-yl]amino]quinazoline-8-carboxamide Chemical class C12=CN=CN=C2C(C(=O)N)=CC=C1NC1CNCC1C1=CC=CC(OC(F)(F)F)=C1 KEKMTFSRYLVCEZ-UHFFFAOYSA-N 0.000 description 1
- MCNGEVIGERVBTB-UHFFFAOYSA-N 5-[[4-chloro-3-(trifluoromethyl)phenyl]methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=C(Cl)C(C(F)(F)F)=C1 MCNGEVIGERVBTB-UHFFFAOYSA-N 0.000 description 1
- ZCKDTUWMABZVAA-UHFFFAOYSA-N 5-[[4-fluoro-3-(trifluoromethyl)phenyl]methylamino]quinoline-8-carboxamide Chemical class C12=CC=CN=C2C(C(=O)N)=CC=C1NCC1=CC=C(F)C(C(F)(F)F)=C1 ZCKDTUWMABZVAA-UHFFFAOYSA-N 0.000 description 1
- KDJUPPVUTIDCIZ-UHFFFAOYSA-N 5-[methyl(2-phenylethyl)amino]quinazoline-8-carboxamide Chemical class C=1C=C(C(N)=O)C2=NC=NC=C2C=1N(C)CCC1=CC=CC=C1 KDJUPPVUTIDCIZ-UHFFFAOYSA-N 0.000 description 1
- SQKCWKYFTKEUCJ-UHFFFAOYSA-N 5-aminoquinoline-8-carbonitrile Chemical compound C1=CC=C2C(N)=CC=C(C#N)C2=N1 SQKCWKYFTKEUCJ-UHFFFAOYSA-N 0.000 description 1
- RPMSTHVPCJNFMM-UHFFFAOYSA-N 5-aminoquinoline-8-carboxamide Chemical class C1=CN=C2C(C(=O)N)=CC=C(N)C2=C1 RPMSTHVPCJNFMM-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- WFTAAIWHBZYBTD-UHFFFAOYSA-N 5-bromo-8-methylquinazoline Chemical compound N1=CN=C2C(C)=CC=C(Br)C2=C1 WFTAAIWHBZYBTD-UHFFFAOYSA-N 0.000 description 1
- IAQNFOPKXLQOLR-UHFFFAOYSA-N 5-bromoquinazoline Chemical compound C1=NC=C2C(Br)=CC=CC2=N1 IAQNFOPKXLQOLR-UHFFFAOYSA-N 0.000 description 1
- DJVLTFWZJRRQLD-UHFFFAOYSA-N 5-bromoquinazoline-8-carbaldehyde Chemical compound C1=NC=C2C(Br)=CC=C(C=O)C2=N1 DJVLTFWZJRRQLD-UHFFFAOYSA-N 0.000 description 1
- NPLPBRIDHFAGPQ-UHFFFAOYSA-N 5-bromoquinoline-8-carbaldehyde Chemical compound C1=CC=C2C(Br)=CC=C(C=O)C2=N1 NPLPBRIDHFAGPQ-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- KKASWOGQJXWOHK-UHFFFAOYSA-N 8-methylquinazoline Chemical compound N1=CN=C2C(C)=CC=CC2=C1 KKASWOGQJXWOHK-UHFFFAOYSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001044369 Amphion Species 0.000 description 1
- 102100033972 Amyloid protein-binding protein 2 Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BZLMJTAVHBVWPP-UHFFFAOYSA-N C1CNCC1CC2=C(C=C(C=C2)C(=O)N)CC3CCNC3 Chemical compound C1CNCC1CC2=C(C=C(C=C2)C(=O)N)CC3CCNC3 BZLMJTAVHBVWPP-UHFFFAOYSA-N 0.000 description 1
- GNLGXTRADJVTBP-UHFFFAOYSA-N CC1=CC=CC=C1N2CCC(CC2)NC3=C4C=NC=NC4=C(C=C3)C(=O)N Chemical class CC1=CC=CC=C1N2CCC(CC2)NC3=C4C=NC=NC4=C(C=C3)C(=O)N GNLGXTRADJVTBP-UHFFFAOYSA-N 0.000 description 1
- PPRMHEBSMYSJIQ-KBXCAEBGSA-N CC1=CC=CC=C1[C@@H]2CN(C[C@H]2CO)C3=C4C=NC=NC4=C(C=C3)C(=O)N Chemical compound CC1=CC=CC=C1[C@@H]2CN(C[C@H]2CO)C3=C4C=NC=NC4=C(C=C3)C(=O)N PPRMHEBSMYSJIQ-KBXCAEBGSA-N 0.000 description 1
- PIRVXKLBTOWDPF-UHFFFAOYSA-N CCC(C(C(CC1)(CN1c(cc1)c(cncn2)c2c1C(N)=O)N=C)=O)c1ccccc1 Chemical compound CCC(C(C(CC1)(CN1c(cc1)c(cncn2)c2c1C(N)=O)N=C)=O)c1ccccc1 PIRVXKLBTOWDPF-UHFFFAOYSA-N 0.000 description 1
- GPYKQOCYDCMGOA-UHFFFAOYSA-N CCCCCC[O] Chemical compound CCCCCC[O] GPYKQOCYDCMGOA-UHFFFAOYSA-N 0.000 description 1
- DZAHXNNEQCZPGJ-UHFFFAOYSA-N CCCCOC(OC)=O.COC(O)=O Chemical compound CCCCOC(OC)=O.COC(O)=O DZAHXNNEQCZPGJ-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- SEEPOQRQNVNTRO-UHFFFAOYSA-N Cc(ccc(Cl)c1)c1N(CC1)CCN1C(C1=CCN=CN=C1C1)=CC=C1C(N=N)O Chemical compound Cc(ccc(Cl)c1)c1N(CC1)CCN1C(C1=CCN=CN=C1C1)=CC=C1C(N=N)O SEEPOQRQNVNTRO-UHFFFAOYSA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 101000785279 Dictyostelium discoideum Calcium-transporting ATPase PAT1 Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000549194 Euonymus europaeus Species 0.000 description 1
- XRVOSXMXAMDHTR-HSZRJFAPSA-N FC=1C=C(C=CC1)[C@@H](CN(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])C)NC1=C2C=CC=NC2=C(C=C1)C(=O)O Chemical compound FC=1C=C(C=CC1)[C@@H](CN(S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])C)NC1=C2C=CC=NC2=C(C=C1)C(=O)O XRVOSXMXAMDHTR-HSZRJFAPSA-N 0.000 description 1
- 101150025764 FGFR3 gene Proteins 0.000 description 1
- 101150009958 FLT4 gene Proteins 0.000 description 1
- 101150048336 Flt1 gene Proteins 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000768016 Homo sapiens AP-1 complex subunit sigma-2 Proteins 0.000 description 1
- 101000779309 Homo sapiens Amyloid protein-binding protein 2 Proteins 0.000 description 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 description 1
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000713296 Homo sapiens Proton-coupled amino acid transporter 1 Proteins 0.000 description 1
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101150081525 LIMK1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- DXRFZHILMCWCNG-UHFFFAOYSA-N N,N-dimethyl-1,8-naphthyridin-2-amine Chemical compound C1=CC=NC2=NC(N(C)C)=CC=C21 DXRFZHILMCWCNG-UHFFFAOYSA-N 0.000 description 1
- MHRDOVDWLMWCAJ-CQSZACIVSA-N N-[(2S)-2-amino-2-(3-fluorophenyl)ethyl]-4-nitrobenzenesulfonamide Chemical compound N[C@H](CNS(=O)(=O)c1ccc(cc1)[N+]([O-])=O)c1cccc(F)c1 MHRDOVDWLMWCAJ-CQSZACIVSA-N 0.000 description 1
- CZZPTQNISBIQOI-UHFFFAOYSA-N NC(c(cc1)c2ncccc2c1NCc1cccc(F)c1)O Chemical compound NC(c(cc1)c2ncccc2c1NCc1cccc(F)c1)O CZZPTQNISBIQOI-UHFFFAOYSA-N 0.000 description 1
- ARDCHIOWMUVWOX-XPCCGILXSA-N NC(c(cc1)c2ncncc2c1NC(CNC1)[C@H]1c1cc(F)cc(Cl)c1)=O Chemical compound NC(c(cc1)c2ncncc2c1NC(CNC1)[C@H]1c1cc(F)cc(Cl)c1)=O ARDCHIOWMUVWOX-XPCCGILXSA-N 0.000 description 1
- XMDIFFNNRQWCSJ-UHFFFAOYSA-N NC1OC1c(cc1)c2ncccc2c1NCc(cc1)cc(F)c1F Chemical compound NC1OC1c(cc1)c2ncccc2c1NCc(cc1)cc(F)c1F XMDIFFNNRQWCSJ-UHFFFAOYSA-N 0.000 description 1
- 101150111783 NTRK1 gene Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- YXCWXBIECMWDNI-UHFFFAOYSA-N O=C(C1(CNC(OCc2ccccc2)=O)CNCCC1)Nc1ccccc1 Chemical compound O=C(C1(CNC(OCc2ccccc2)=O)CNCCC1)Nc1ccccc1 YXCWXBIECMWDNI-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- JXASPPWQHFOWPL-UHFFFAOYSA-N Tamarixin Natural products C1=C(O)C(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 JXASPPWQHFOWPL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- XVTUILQTJLXDEI-UHFFFAOYSA-N acetamidourea Chemical group CC(=O)NNC(N)=O XVTUILQTJLXDEI-UHFFFAOYSA-N 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- DRKDJDUPOFSMEU-UHFFFAOYSA-N acetic acid;potassium Chemical compound [K].[K].CC(O)=O DRKDJDUPOFSMEU-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000002714 alpha-linolenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FJWWBICVZIPHLO-VWMHFEHESA-N benzene (2R)-3-sulfonylpyrrolidine-2-carboxylic acid Chemical compound S(=O)(=O)=C1[C@H](NCC1)C(=O)O.C1=CC=CC=C1 FJWWBICVZIPHLO-VWMHFEHESA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQLARKAOVCMSQV-UHFFFAOYSA-N benzyl n-(piperidin-3-ylmethyl)carbamate Chemical class C=1C=CC=CC=1COC(=O)NCC1CCCNC1 OQLARKAOVCMSQV-UHFFFAOYSA-N 0.000 description 1
- QGZPSEQCVNAHGG-UHFFFAOYSA-N benzyl n-(pyrrolidin-3-ylmethyl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCC1CCNC1 QGZPSEQCVNAHGG-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N cyclobenzothiazole Natural products C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- ZLSVALLKHLKICA-UHFFFAOYSA-N hexan-1-amine;hydrobromide Chemical compound [Br-].CCCCCC[NH3+] ZLSVALLKHLKICA-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000005644 linolenyl group Chemical group 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- ORVDUHXYIGSKMV-UHFFFAOYSA-N n-(pyrrolidin-3-ylmethyl)-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC2CNCC2)=C1 ORVDUHXYIGSKMV-UHFFFAOYSA-N 0.000 description 1
- YWUQVHCZRYQTHA-OAHLLOKOSA-N n-[(2s)-2-amino-2-(3-fluorophenyl)ethyl]-n-methyl-4-nitrobenzenesulfonamide Chemical compound C1([C@H](N)CN(C)S(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=CC(F)=C1 YWUQVHCZRYQTHA-OAHLLOKOSA-N 0.000 description 1
- GETJIDBYVFIZCO-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-n-methylpyrrolidin-3-amine Chemical compound C1CNCC1N(C)CC1=CC=C(Cl)C(Cl)=C1 GETJIDBYVFIZCO-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- PSVZYZVUAGRCLN-UHFFFAOYSA-N n-benzyl-n-[2-(dimethylamino)ethyl]pyrrolidine-3-carboxamide Chemical class C1CNCC1C(=O)N(CCN(C)C)CC1=CC=CC=C1 PSVZYZVUAGRCLN-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- DBGFNLVRAFYZBI-UHFFFAOYSA-N n-methylpyridin-3-amine Chemical compound CNC1=CC=CN=C1 DBGFNLVRAFYZBI-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZFFJTSYIJQQLE-UHFFFAOYSA-N n-pyrrolidin-3-yl-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NC2CNCC2)=C1 YZFFJTSYIJQQLE-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 1
- DQZWTJKAULHSBX-UHFFFAOYSA-N piperazine;pyridine-3-carboxylic acid Chemical compound C1CNCCN1.OC(=O)C1=CC=CN=C1 DQZWTJKAULHSBX-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- SBMSLRMNBSMKQC-UHFFFAOYSA-N pyrrolidin-1-amine Chemical class NN1CCCC1 SBMSLRMNBSMKQC-UHFFFAOYSA-N 0.000 description 1
- NGXSWUFDCSEIOO-UHFFFAOYSA-N pyrrolidin-3-amine Chemical compound NC1CCNC1 NGXSWUFDCSEIOO-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical class NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 1
- MGYXPFHVGMHTGE-UHFFFAOYSA-N quinazolin-3-ium;bromide Chemical compound Br.N1=CN=CC2=CC=CC=C21 MGYXPFHVGMHTGE-UHFFFAOYSA-N 0.000 description 1
- UPGZAERNNNZSPM-UHFFFAOYSA-N quinazoline-8-carboxylic acid Chemical compound N1=CN=C2C(C(=O)O)=CC=CC2=C1 UPGZAERNNNZSPM-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- OGCCBDIYOAFOGK-MRVPVSSYSA-N tert-butyl (3r)-3-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@H](CN)C1 OGCCBDIYOAFOGK-MRVPVSSYSA-N 0.000 description 1
- OGCCBDIYOAFOGK-QMMMGPOBSA-N tert-butyl (3s)-3-(aminomethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](CN)C1 OGCCBDIYOAFOGK-QMMMGPOBSA-N 0.000 description 1
- WUYFSSRJLALGJT-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-3-(phenylcarbamoyl)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1(CN)C(=O)NC1=CC=CC=C1 WUYFSSRJLALGJT-UHFFFAOYSA-N 0.000 description 1
- ZLVKJMCJYMCTHN-UHFFFAOYSA-N tert-butyl 3-[(3-fluorophenyl)carbamoyl]-4-(2-trimethylsilylethoxycarbonylamino)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(NC(=O)OCC[Si](C)(C)C)C1C(=O)NC1=CC=CC(F)=C1 ZLVKJMCJYMCTHN-UHFFFAOYSA-N 0.000 description 1
- BOCWISBLHUHOIU-UHFFFAOYSA-N tert-butyl 3-amino-4-(3-chloro-5-fluorophenyl)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(N)C1C1=CC(F)=CC(Cl)=C1 BOCWISBLHUHOIU-UHFFFAOYSA-N 0.000 description 1
- NSQMWLMHMVFFRZ-UHFFFAOYSA-N tert-butyl 3-amino-4-[3-(trifluoromethyl)phenyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(N)C1C1=CC=CC(C(F)(F)F)=C1 NSQMWLMHMVFFRZ-UHFFFAOYSA-N 0.000 description 1
- DOLJNLKIUYMLHU-UHFFFAOYSA-N tert-butyl 3-amino-4-[4-(trifluoromethoxy)phenyl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC(N)C1C1=CC=C(OC(F)(F)F)C=C1 DOLJNLKIUYMLHU-UHFFFAOYSA-N 0.000 description 1
- CMIBWIAICVBURI-UHFFFAOYSA-N tert-butyl 3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C1 CMIBWIAICVBURI-UHFFFAOYSA-N 0.000 description 1
- NOVUBWBKZLPMFG-UHFFFAOYSA-N tert-butyl 4-(2-amino-1-phenylethyl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(CN)C1=CC=CC=C1 NOVUBWBKZLPMFG-UHFFFAOYSA-N 0.000 description 1
- KHPQHXGYYXYTDN-UHFFFAOYSA-N tert-butyl n-(piperidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCCNC1 KHPQHXGYYXYTDN-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- PSEQWFPWQRZBOO-UHFFFAOYSA-M tetrahexylazanium;benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.CCCCCC[N+](CCCCCC)(CCCCCC)CCCCCC PSEQWFPWQRZBOO-UHFFFAOYSA-M 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- BAZVSMNPJJMILC-UHFFFAOYSA-N triadimenol Chemical compound C1=NC=NN1C(C(O)C(C)(C)C)OC1=CC=C(Cl)C=C1 BAZVSMNPJJMILC-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- GQHWSLKNULCZGI-UHFFFAOYSA-N trifluoromethoxybenzene Chemical compound FC(F)(F)OC1=CC=CC=C1 GQHWSLKNULCZGI-UHFFFAOYSA-N 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N trimethylmethane Natural products CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
本发明提供了通式(I)所示的新的杂环羧酰胺化合物,它们的制备及其用于治疗过度增殖性疾病诸如癌症的用途,
Description
技术领域
本发明涉及一系列可用于治疗哺乳动物的过度增殖性疾病诸如癌症的杂环羧酰胺化合物。本发明还包括所述化合物在治疗哺乳动物尤其是人的过度增殖性疾病的用途,以及包含所述化合物的药物组合物。
发明背景
蛋白激酶组成一大族担负细胞内多种信号转导过程控制的结构相关酶(Hardie,G.和Hanks,S.(1995)The Protein Kinase Facts Book.I和II,Academic Press,SanDiego,CA)。通过它们磷酸化的底物(例如蛋白-酪氨酸、蛋白-丝氨酸/苏氨酸、脂质等),可将激酶分成多族。已确定了一般对应于这些激酶各族的序列模体(例如,Hanks,S.K.,Hunter,T.,FASEB J.,9:576-596(1995);Knighton,等人,Science,253:407-414(1991);Hiles等人,Cell,70:419-429(1992);Kunz等人,Cell,73:585-596(1993);Garcia-Bustos,等人,EMBO J.,13:2352-2361(1994))。
蛋白激酶可由其调节机制表征。这些机制包括例如自磷酸化作用、由其它激酶转磷酸作用、蛋白质-蛋白质相互作用、蛋白质-脂质相互作用和蛋白质-多核苷酸相互作用。单个蛋白激酶可由多于一种机制调节。
通过将磷酸基团加到靶蛋白,激酶可调节很多不同的细胞过程,包括但不限于增殖、分化、细胞凋亡、运动性、转录、翻译及其他信号传导过程。这些磷酸化事件充当能够调节或调整靶蛋白生物功能的分子通断开关。靶蛋白的磷酸化响应于多种胞外信号(激素、神经递质、生长和分化因子等)、细胞周期事件、环境或营养应激等而发生。适合的蛋白激酶在信号传导通路中起作用以活化或钝化(直接或间接)例如代谢酶、调节蛋白、受体、细胞骨架蛋白、离子通道或泵或转录因子。由蛋白磷酸化控制缺陷导致的不受控的信号传导涉及多种疾病,包括例如炎症、癌症、过敏/哮喘、免疫系统疾病和病症、中枢神经系统疾病和病症及血管生成。
蛋白激酶70S6K,即70kDa核糖体蛋白激酶p70S6K(也称为SK6、p70/p85S6激酶、p70/p85核糖体S6激酶和pp70S6K)是蛋白激酶的AGC亚家族的成员。p70S6K是丝氨酸-苏氨酸激酶,其是磷脂酰肌醇3激酶(PI3K)/AKT通路的组成部分。p70S6K为PI3K的下游部分,且通过响应多种有丝分裂原、激素和生长因子在多个位点的磷酸化而被激活。由于雷帕霉素起到抑制p70S6K活性的作用,p70S6K活性也受包含mTOR的复合物(TORC1)的控制。p70S6K通过PI3K下游靶点AKT和PKCζ调节。Akt直接磷酸化并钝化TSC2,由此激活mTOR。此外,对于被渥曼青霉素抑制而不被雷帕霉素抑制的p70S6K的突变体等位基因的研究表明PI3K通路可以不依赖mTOR活性的调节而对p70S6K产生作用。
酶p70S6K通过S6核糖体蛋白的磷酸化而调控蛋白合成。S6磷酸化与翻译装置(translational apparatus)的mRNA编码组件的翻译的增加相关,所述翻译装置包括核糖体蛋白和翻译延伸因子(其表达增加对细胞生长和增殖是必不可少的)。这些mRNA在其5'转录起始端(称为5'TOP)包含寡嘧啶片段,已证明这对于其在翻译水平的调节是必不可少的。
除了参与翻译之外,p70S6K激活还涉及细胞周期控制、神经细胞分化、在肿瘤转移中重要的细胞运动性和细胞响应的调节、免疫应答和组织修复。p70S6K抗体破坏了大鼠成纤维细胞进入S期所驱动的促有丝分裂响应,这就表明了p70S6K功能在细胞周期中从G1期至S期的进程中是必不可少的。此外,已经确定在细胞周期的G1期至S期雷帕霉素对细胞周期增殖的抑制是其抑制生成过度磷酸化的激活形式的p70S6K的结果。
p70S6K肿瘤细胞增殖和保护细胞免于细胞凋亡中的作用受到支持,这是基于其在肿瘤组织中参与生长因子受体信号转导、过表达和激活。例如,RNA印迹分析和蛋白质印迹分析表明,PS6K基因的扩增分别伴有mRNA和蛋白质表达的相应增加(Cancer Res.(1999)59:1408-11-PS6K在乳腺癌中定位于染色体区17q23及其扩增的测定(Localization ofPS6K to Chromosomal Region17q23and Determination of Its Amplification inBreast Cancer))。
染色体17q23在以下肿瘤和癌症中扩增:高达20%的原发性乳腺肿瘤、87%含有BRCA2突变的乳腺肿瘤和50%含有BRCA1突变的肿瘤以及其它癌症类型,例如胰腺癌、膀胱癌和成神经细胞瘤(参见M.Barlund,O.Monni,J.Kononen,R.Cornelison,J.Torhorst,G.Sauter,O.-P.Kallioniemi和Kallioniemi A.,Cancer Res.,2000,60:5340-5346)。研究表明,17q23在乳腺癌中的扩增涉及PAT1、RAD51C、PS6K和SIGMA1B基因(Cancer Res.(2000):60,第5371-5375页)。
p70S6K基因已被鉴定为这些部位扩增和过表达的靶点,并且观察到扩增和预后不良之间在统计上显著相关。在用上游激酶mTOR的抑制剂CCI-779(雷帕霉素酯)治疗的肾癌患者中,观察到p70S6K激活的临床抑制。据报道,疾病进程和p70S6K活性抑制之间有显著的线性相关性。在响应能量应激时肿瘤抑制因子LKB1激活AMPK,AMPK磷酸化TSC1/2复合物,并使得其钝化mTOR/p70S6K通路。LKB1中的突变引起波伊茨-耶格综合征(Peutz-Jegherssyndrome PJS),患有PJS的患者发展为的癌症可能性是一般人群的15倍。此外,1/3的肺腺癌潜伏有未激活的LKB1突变。p70S6K涉及代谢疾病和障碍。据报道,缺乏p70S6K避免患年龄和饮食诱发的肥胖症并同时提高胰岛素敏感性。基于这些发现,支持了p70S6K在肥胖症、糖尿病、代谢综合征、胰岛素抵抗、高血糖、高氨基酸血症和高脂血症等代谢疾病和障碍中的作用。
在WO03/064397、WO04/092154、WO05/054237、WO05/056014、WO05/033086、WO05/117909、WO05/039506、WO06/120573、WO06/136821、WO06/071819、WO06/131835、WO08/140947和PCT/US10/000313中公开了被描述为适于抑制p70S6K的化合物。
发明内容
本发明的目的是提供调节激酶活性的新化合物。该蛋白激酶调节包括但不限于p70S6K抑制和AKT抑制,其用于治疗过度增殖性疾病,尤其是与以上提及的蛋白激酶的活动过度相关的那些,诸如哺乳动物中的癌症,所述化合物在活性以及溶解度、代谢清除率和生物利用度特性方面具有优良的药理性质。
因此,本发明提供了新的杂环状羧酰胺及其可药用盐、溶剂化物或前药,它们是激酶抑制剂且可用于治疗以上提及的疾病。
所述化合物为通式(I)化合物及其可药用盐、溶剂化物、盐的溶剂化物或前药,
其中:
X是N、或者C-R4;
Y是N-R5、O、或者不存在;
R1是L1-R6、L1-R6-L2-R7;
R2是H、Hal、OH、OA、CN、NH2、或者NHA;
R3是H、CH3、或者C(Hal)3;
R4是H、Hal、OH、COOH、NH2、或者CN;
R5是H、LA或者是具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被-NH-所替代,或者
R5、R1一起形成具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被O原子和/或–NH-、-NA-、-N(L1-R6)-、-CHA-、-CA2-、CH(L1-R6)-或者-CO-基团所替代,并且所述单环烷基可以被NH2取代;
L1、L2独立地是单键,或者是具有1、2、3、4或5个C原子的无支链的或有支链的烷基,所述烷基可以未被取代或被Hal、OH、NH2、NH(LA)、N(LA)2单取代或二取代,其中1个或2个CH2基团可以被O原子或者被-CO-、-NH-、-N(LA)-、-CONH-、-N(LA)COO-或者-NHCO-基团所替代;
R6是Ar或者是具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被O原子和/或被–NH-、-NA-、-CHA-、-CO-或者-CONHA-基团所替代;
Ar是具有0、1、2、3或4个N、O和/或S原子和5、6、8、9或10个骨架原子的单环或二环的芳族碳环或杂环,所述碳环或杂环可以未被取代或相互独立地被Hal、A、OA、OH、NH2、或者NHA单取代、二取代或三取代;
A是具有1、2、3、4、5或6个C原子的无支链的或有支链的直链烷基或者环状烷基,其中1个或2个CH2基团可以被O原子和/或–NH-、-NHCOAr或者–CONHAr基团所替代,其中1-3个H原子可以被Hal所替代,并且其中1个或2个CH3基团可以被NH2、OH、NH(LA)或者N(LA)2基团所替代;
LA是具有1、2、3或4个C原子的无支链的或有支链的直链烷基,其中1、2或3个H原子可以被Hal(例如甲基、乙基和三氟甲基)所替代;以及
Hal是F、Cl、Br或者I。
一般地,出现超过一次的全部残基可以是相同或不同,即它们是相互独立的。除非另外说明,上下文中的残基和参数具有如通式(I)标示下的含义。
因此,本发明特别涉及通式(I)化合物,其中所述基团中至少一个具有下文所示的优选的含义。
“Hal”表示氟、氯、溴或碘,特别是氟或氯。
“A”表示例如,甲基,此外表示乙基、丙基、异丙基、丁基、异丁基、仲丁基或叔丁基,此外还表示戊基、1-、2-或3-甲基丁基、1,1-、1,2-或2,2-二甲基丙基、1-乙基丙基、己基、1-、2-、3-或4-甲基戊基、1,1-、1,2-、1,3-、2,2-、2,3-或3,3-二甲基丁基、1-或2-乙基丁基、1-乙基-1-甲基丙基、1-乙基-2-甲基丙基、1,1,2-或1,2,2-三甲基丙基。
“A”还表示如上文所定义的烷基,其中一个或两个CH2基团可以被O或S原子所替代和/或被NH、N(LA)、CONH、NHCO或-CH=CH-基团所替代,和/或还有1-3个H原子可以被F和/或Cl所替代,例如,三氟甲基、五氟乙基、1,1-二氟甲基、1,1,1-三氟乙基、甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基或叔丁氧基。
在“A”的其它实例中,一个或两个CH3基团被OH,SH,NH2,N(LA)H,N(LA)2或CN替代,例如,N,N’-二甲基氨基烷基、2-氨基乙基、3-氨基丙基、4-氨基丁基、5-氨基戊基、3-氨基甲基环丁基或氰基烷基。环状A优选地表示环丙基、环丁基、环戊基、环己基或环庚基。
“LA”表示具有1、2、3或4个C原子的无支链的或有支链的直链烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基或叔丁基。
“Ar”表示例如,未被取代的苯基、萘基或联苯基,此外还优选例如,苯基、萘基或联苯基,其各自被A、氟、氯、溴、碘、羟基、甲氧基、乙氧基、丙氧基、丁氧基、戊基氧基、己基氧基、硝基、氰基、甲酰基、乙酰基、丙酰基、三氟甲基、氨基、甲基氨基、乙基氨基、二甲基氨基、二乙基氨基、苄基氧基、磺酰氨基、甲基磺酰氨基、乙基磺酰氨基、丙基磺酰氨基、丁基磺酰氨基、二甲基磺酰氨基、苯基磺酰氨基、羧基、甲氧基羰基、乙氧基羰基、氨基羰基单、二或三取代。
“Ar”还表示邻-、间-或对-甲苯基、邻-、间-或对-乙基苯基、邻-、间-或对-丙基苯基、邻-、间-或对-异丙基苯基、邻-、间-或对-叔丁基苯基、邻-、间-或对-羟基苯基、邻-、间-或对-硝基苯基、邻-、间-或对-氨基苯基、邻-、间-或对-(N-甲基氨基)苯基、邻-、间-或对-(N-甲基氨基羰基)苯基、邻-、间-或对-乙酰氨基苯基、邻-、间-或对-甲氧基苯基、邻-、间-或对-乙氧基苯基、邻-、间-或对-乙氧基羰基苯基、邻-、间-或对-(N,N-二甲基氨基)苯基、邻-、间-或对-(N,N-二甲基氨基羰基)苯基、邻-、间-或对-(N-乙基氨基)苯基、邻-、间-或对-(N,N-二乙基氨基)苯基、邻-、间-或对-氟苯基、邻-、间-或对-溴苯基、邻-、间-或对-氯苯基、邻-、间-或对-(甲基磺酰氨基)苯基、邻-、间-或对-(甲磺酰基)苯基,还优选2,3-、2,4-、2,5-、2,6-、3,4-或3,5-二氟苯基、2,3-、2,4-、2,5-、2,6-、3,4-或3,5-二氯苯基、2,3-、2,4-、2,5-、2,6-、3,4-或3,5-二溴苯基、2,4-或2,5-二硝基苯基、2,5-或3,4-二甲氧基苯基、3-硝基-4-氯苯基、3-氨基-4-氯-、2-氨基-3-氯-、2-氨基-4-氯-、2-氨基-5-氯-或2-氨基-6-氯苯基、2-硝基-4-N,N-二甲基氨基-或3-硝基-4-N,N-二甲基氨基苯基、2,3-二氨基苯基、2,3,4-、2,3,5-、2,3,6-、2,4,6-或3,4,5-三氯苯基、2,4,6-三甲氧基苯基、2-羟基-3,5-二氯苯基、对-碘苯基、3,6-二氯-4-氨基苯基、4-氟-3-氯苯基、2-氟-4-溴苯基、2,5-二氟-4-溴苯基、3-溴-6-甲氧基苯基、3-氯-6-甲氧基苯基、3-氯-4-乙酰氨基苯基、3-氟-4-甲氧基苯基、3-氨基-6-甲基苯基、3-氯-4-乙酰氨基苯基或2,5-二甲基-4-氯苯基、(4-甲氧基苯基)甲基、(3-甲氧基苯基)甲基、(4-甲氧基苯基)乙基、(3-甲氧基苯基)乙基。
“Ar”还优选地表示2-、3-或4-苯基、2-、3-或4-苯基甲基、2-、3-或4-苯基乙基、2-或3-呋喃基、2-或3-噻吩基、1-、2-或3-吡咯基、1-、2、4-或5-咪唑基、1-、3-、4-或5-吡唑基、2-、4-或5-噁唑基、3-、4-或5-异噁唑基、2-、4-或5-噻唑基、3-、4-或5-异噻唑基、2-、3-或4-吡啶基、2-、3-或4-吡啶基甲基、2-、3-或4-吡啶基乙基、2-、4-、5-或6-嘧啶基、2-、3-、5-或6-吡嗪-1-或4-基,此外还优选地表示1,2,3-三唑-1-、-4-或-5-基、1,2,4-三唑-1-、-3-或5-基、1-或5-四唑基、1,2,3-噁二唑-4-或-5-基、1,2,4-噁二唑-3-或-5-基、1,3,4-噁二唑-2-基、1,3,4-噻二唑-2-或-5-基、1,2,4-噻二唑-3-或-5-基、1,2,3-噻二唑-4-或-5-基、3-或4-哒嗪基、1-、2-、3-、4-、5-、6-或7-吲哚基、2-、3-、4-或5-异吲哚基、2-、6-或8-嘌呤基、1-、2-、4-或5-苯并咪唑基、1-、3-、4-、5-、6-或7-苯并吡唑基、2-、4-、5-、6-或7-苯并噁唑基、3-、4-、5-、6-或7-苯并异噁唑基、2-、4-、5-、6-或7-苯并噻唑基、2-、4-、5-、6-或7-苯并异噻唑基、4-、5-、6-或7-苯并-2,1,3-噁二唑基、1-、3-、4-、5-、6-、7-或8-异喹啉基、3-、4-、5-、6-、7-或8-喹啉基、2-、4-、5-、6-、7-或8-喹唑啉基、喹喔啉-2-、3-、4-或5-基、4-、5-或6-酞嗪基、2-、3-、5-、6-、7-或8-2H-苯并-1,4-噁嗪基,还优选1,3-苯并间二氧杂环戊烯-2-、4-或5-基、噻吩-2-或3-基、1,4-苯并二噁烷-6-基、2,1,3-苯并噻二唑-4-或-5-基或2,1,3-苯并噁二唑-5-基、呋喃-2-或3-基、2,3-二氢-苯并呋喃-2-、3-、4-或5-基,其各自未被取代或可以被例如羰基氧、F、Cl、Br、甲基、乙基、丙基、苯基、苄基、-CH2-环己基、羟基、甲氧基、乙氧基、氨基、甲基氨基、二甲基氨基、硝基、氰基、羧基、甲氧基羰基、氨基羰基、甲基氨基羰基、二甲基氨基羰基、乙酰氨基、脲基、甲磺酰基氨基、甲酰基、乙酰基、氨基磺酰基和/或甲磺酰基单、二或三取代。
特别优选的是符合通式(I)的子通式1至10所示的化合物,其中:
在子通式1中,
X是N,
Y是N-R5,
在子通式2中,
X是N,
Y是N-R5,
R5、R1一起形成具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被–NH-、-NA-、-N(L1-R6)-、-CHA-、-CA2-、CH(L1-R6)-或者-CO-基团所替代,并且所述单环烷基可以被NH2取代,
在子通式3中,
X是N,
Y是N-R5,
R5、R1一起形成具有4、5或6个环原子的单环烷基,其中1个CH2基团可以被-N(L1-R6)-基团所替代,并且所述单环烷基可以被NH2取代,
在子通式4中,
X是N,
Y是N-R5,
R5、R1一起形成具有4、5或6个环原子的单环烷基,其中1个CH2基团可以被-N(L1-R6)-基团所替代,并且所述单环烷基可以被NH2取代,
L1是键、-CONH-、-NHCO-、-CONHCH2-、CH2CONH-,
在子通式5中,
X是N,
Y是N-R5,
R5、R1一起形成具有4、5或6个环原子的单环烷基,其中1个CH2基团可以被-N(L1-R6)-基团所替代,并且所述单环烷基可以被NH2取代,
R6是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、C(Hal)3O单取代、二取代或三取代,
在子通式6中,
X是N,
Y是N-R5,
X是N,
Y是N-R5,
R5、R1一起形成具有4、5或6个环原子的单环烷基,其中1个CH2基团可以被-N(L1-R6)-基团所替代,并且所述单环烷基可以被NH2取代,
L1是鍵、-CONH-、-NHCO-、-CONHCH2-、CH2CONH-,
R6是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代、二取代或三取代,
在子通式7中,
X是N,
Y是NH,
R1是L1-R6-L2-R7,
L1,L2是鍵,
R6是具有4、5或6个环原子的单环烷基,其中1个CH2基团可以被-NH基团所替代,
R7是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代、二取代或三取代,
在子通式8中,
X是N,
Y是NH,
R1是L1-R6-L2-R7,
L1,L2是鍵,
R6是哌啶基或吡咯烷基,
R7是苯基,所述苯基被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代或二取代,
在子通式9中,
X是N,
Y是NH,
R1是L1-R6-L2-R7,
L1,L2是鍵,
R6是或
R7是苯基,所述苯基被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代或二取代,
在子通式10中,
X是N,
Y是NH,
R1是L1-R6,
R6是苯基,所述苯基未被取代或独立地被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代、二取代或三取代,
其余的残基具有如上通式(I)标示下的含义。
本发明化合物可为前药化合物形式。“前药化合物”是指于生物体中在生理学条件下可以通过例如氧化反应、还原反应、水解反应等转化为本发明的生物学活性化合物的衍生物,每种反应均可以在有酶或没有酶的参与的情况下下进行。前药的实例为下述情况的化合物:其中本发明化合物中的氨基基团被酰化、烷基化或磷酸化,例如,二十酰基氨基、丙氨酰氨基、新戊酰氧基甲基氨基;或其中羟基基团被酰化、烷基化、磷酸化或转化为硼酸酯,例如乙酰基氧基、棕榈酰氧基、新戊酰氧基、琥珀酰氧基、富马酰氧基、丙氨酰氧基;或其中羧基基团被酯化或酰胺化;或其中硫羟基基团与载体分子(例如肽)形成二硫桥,所述载体分子选择性地将药物递送至靶点和/或至细胞溶胶。这些化合物可根据已知的方法由本发明化合物制得。前药的其它实例为如下的化合物,其中本发明化合物中的羧酸酯例如被转化为烷基-、芳基-、胆碱、氨基、酰氧基甲酯、亚麻酰基(linolenoyl)-酯。
本发明化合物的代谢物也在本发明范围内。
当本发明化合物或其前药的互变异构(例如,酮-烯醇互变异构)现象存在时,既要求保护它们分别的单个形式(例如,酮或烯醇形式),也要求保护其任意比例的混合物。这同样适用于它们的立体异构体,例如,对映异构体、顺/反异构体、构象异构体等。
如有需要,异构体可根据本领域已知的方法(例如液相色谱法)分离。这同样适用于它们的对映异构体,例如,采用手性固定相分离。此外,对映异构体可通过转化为非对映异构体进行分离,即与对映异构纯的辅助化合物偶连,随后分离所得的非对映异构体并裂解辅助残基。或者,本发明化合物的任何对映异构体可用光学纯原料由立体选择性合成获得。
本发明化合物可以是可药用盐或溶剂化物形式。术语“可药用盐”是指由可药用的无毒碱或酸(包括无机碱或酸和有机碱或酸)制得的盐。在本发明化合物含有一个或多个酸性或碱性基团的情况下,本发明同样包括它们相应的药学上或毒物学上可接受的盐,尤其是它们药学上可利用的盐。因此,含有酸性基团的本发明化合物可以盐形式存在,并且根据本发明,可以作为例如碱金属盐、碱土金属盐或铵盐使用。更多此类盐的精确实例包括:钠盐、钾盐、钙盐、镁盐或含有氨或有机胺(例如,乙基胺、乙醇胺、三乙醇胺或氨基酸)的盐。含有一个或多个碱性基团(即,可被质子化的基团)的本发明化合物可以盐形式存在,并且根据本发明,可以与无机或有机酸形成的加成盐形式存在。适当的酸的实例包括盐酸、氢溴酸、磷酸、硫酸、硝酸、甲磺酸、对甲苯磺酸、萘二磺酸、草酸、乙酸、酒石酸、乳酸、水杨酸、苯甲酸、甲酸、丙酸、新戊酸、二乙基乙酸、丙二酸、琥珀酸、庚二酸、富马酸、马来酸、苹果酸、氨基磺酸、苯基丙酸、葡糖酸、抗坏血酸、异烟酸、柠檬酸、己二酸和其它本领知的酸。如果本发明化合物在分子中同时包含酸性和碱性基团,那么除了所述盐形式外,本发明同样包含内盐或内铵盐(两性离子)。所述各盐可通过本领域技术人员已知的常规方法制得,例如使它们在溶剂或分散剂中与有机或无机酸或碱接触,或者使阴离子或阳离子与其它的盐交换。本发明同样包含如下所有本发明化合物的盐,其因低生理学兼容性不适宜在药物中直接使用,但可作为例如化学反应中间体或在可药用盐的制备中使用。
除非另有说明,术语“被取代的”优选是指被上述取代基取代,其中可能有多种不同程度的取代。
这些化合物的所有的生理学可接受的盐、衍生物、溶剂化物、盐的溶剂化物和立体异构体,包括其所有比例的混合物,也符合本发明。
通式(I)化合物可以具有一个或多个手性中心。因此所述化合物可能以多种对映异构形式出现并可能为外消旋形式或旋光体。因此本发明还涉及这些化合物的旋光体(立体异构体)、对映异构体、外消旋物、非对映异构体和水合物及溶剂化物。
因为本发明化合物的外消旋物或立体异构体的药学活性可能存在差异,可能需要使用对映体。在这些情况下,可采用本领域技术人员已知的或甚至在合成上直接采用的化学或物理方法将终产物甚至中间体拆分成为对映异构化合物。
在分子结构中存在外消旋胺的情况下,混合物可与光学活性拆分试剂形成非对映体。合适的拆分试剂实例为具有光学活性的酸类,如R型或S型的酒石酸、二乙酰酒石酸、二苯甲酰酒石酸、扁桃酸、苹果酸和乳酸,合适的N-保护氨基酸类(例如N-苯甲酰脯氨酸或N苯磺酰脯氨酸),或各种光学活性的樟脑磺酸。借助于光学活性拆分剂(例如固定在硅胶上的二硝基苯甲酰苯基甘氨酸、三醋酸纤维素或碳水化合物的其他衍生物或手性衍生化甲基丙烯酸聚合物)的对映体的色谱拆分法也具有优势。为此目的所使用的合适洗脱剂为含水或含醇的溶剂混合物,例如乙烷/异丙醇/腈,例如比例为82∶15∶3。一种拆分包含酯基(例如乙酰基酯)的外消旋物的巧妙的方法是使用酶、特别是酯酶类。
另外,本发明涉及包含作为活性成分的本发明化合物或其前药化合物或其可药用盐或其溶剂化物以及包含可药用载体的药物组合物。
“药物组合物”是指一种或多种活性成分和组成载体的一种或多种惰性组分以及由下列直接或间接获得的任意产物:任意两种或多种组分组合、复合、聚集,或者一种或多种组分解离,或者一种或多种组分的其它类型的反应或相互作用。因此,本发明药物组合物包括通过本发明化合物和可药用载体混合而制得的任意组合物。
本发明药物组合物可另外含有一种或多种作为活性成分的其它化合物,例如一种或多种另外的本发明化合物、前药化合物或其它p70S6K抑制剂。
药物组合物包括经口、直肠、局部、肠胃外(包括皮下、肌肉内和静脉内)、眼球(眼)、肺(鼻或颊吸入)或鼻给药的适宜组合物,在任何已知的情况中最适宜的途径取决于治疗的病症的性质和严重性以及活性组分的性质。它们可方便地以单位剂量形式存在并采用药物领域已知的任意方法制备。
在一个实施方案中,所述化合物和药物组合物用于治疗以下疾病:癌症,例如脑癌、肺癌、结肠癌、表皮样癌、鳞状细胞癌、膀胱癌、胃癌、胰腺癌、乳腺癌、头癌、颈癌、肾癌、肾的癌、肝癌、卵巢癌、前列腺癌、结直肠癌、子宫癌、直肠癌、食管癌、睾丸癌、妇科癌、甲状腺癌、黑素瘤、恶性血液病,诸如急性髓性白血病、多发性骨髓瘤、慢性髓性白血病、骨髓细胞白血病、神经胶质瘤、卡波西肉瘤,或其它任何类型的实体或液体肿瘤。优选地,治疗的癌症选自乳腺癌、结直肠癌、肺癌、前列腺癌或胰腺癌或成胶质细胞瘤。
本发明还涉及本发明化合物在制备药物中的用途,所述药物用于治疗哺乳动物中与p70S6K活动过度有关的过度增殖性疾病以及由p70S6K级联所调节的疾病,或用于治疗异常增殖介导的病症,例如癌症和炎症。
本发明还涉及用于治疗哺乳动物中与血管发生或血管生成有关的疾病的化合物或药物组合物,其包含治疗有效量的本发明化合物或其可药用盐、前药或水合物以及可药用的载体。
在一个实施方案中,所述化合物或药物组合物可以用于治疗下列疾病:肿瘤血管生成、慢性炎症(例如类风湿性关节炎、炎性肠疾病)、动脉粥样硬化、皮肤病(例如银屑病、湿疹和硬皮病)、糖尿病、糖尿病性视网膜病、早产儿视网膜病和年龄相关性黄斑变性。
本发明还涉及用于抑制哺乳动物中异常细胞生长的化合物或药物组合物,其包含一定量的本发明化合物或其可药用盐或溶剂化物或前药以及一定量的另外的抗癌治疗药物,其中所述化合物、盐、溶剂化物或前药的量与化学治疗剂的量一起对抑制异常细胞生长是有效的。许多抗癌治疗药物目前在本领域内中是已知的。在一个实施方案中,所述抗癌治疗药物是选自以下的化学治疗剂:有丝分裂抑制剂、烷化剂、抗代谢药、嵌入抗生素(intercalating antibiotics)、生长因子抑制剂、细胞周期抑制剂、酶、拓扑异构酶抑制剂、生物学应答调节剂、抗激素、血管生成抑制剂和抗雄激素。在另一个实施方案中,所述抗癌治疗药物是选自以下的抗体:贝伐单抗、CD40-特异性抗体、chTNT-1/B、地舒单抗、扎木单抗、IGF1R-特异性抗体、林妥珠单抗、依决洛单抗、WX G250、利妥昔单抗、替西木单抗、曲妥单抗和西妥昔单抗。在另一个实施方案中,所述抗癌治疗药物是另一种蛋白激酶的抑制剂,所述蛋白激酶诸如Akt、Axl、Aurora A、Aurora B、dyrk2、epha2、fgfr3、igf1r、IKK2、JNK3、Vegfr1、Vegfr2、Vegfr3(也称为Flt-4)、KDR、MEK、MET、Plk1、RSK1、Src、TrkA、Zap70、cKit、bRaf、EGFR、Jak2、PI3K、NPM-Alk、c-Abl、BTK、FAK、PDGFR、TAK1、LimK、Flt-3、PDK1和Erk。
本发明还涉及抑制哺乳动物中异常细胞生长或治疗过度增殖性疾病的方法,该方法包括向哺乳动物施用一定量的本发明化合物或其可药用盐或溶剂化物或前药,与手术或放射治疗联合使用,其中所述化合物、盐、溶剂化物或前药的量联合放射治疗对抑制哺乳动物中的异常细胞生长或治疗过度增殖性疾病是有效的。施用放射治疗的技术在本领域中是已知的,并且这些技术可用于本文中所述的联合治疗中。在该联合治疗中,本发明化合物的施用可如本文所述确定。一般认为,本发明化合物可以使得异常细胞对放射治疗更为敏感,从而可以杀死和/或抑制此类细胞生长。
因此,本发明还涉及使哺乳动物中的异常细胞对放射治疗敏感化的方法,该方法包括向哺乳动物施用一定量的本发明化合物或其可药用盐、溶剂化物或前药,所述量可以有效地使得异常细胞对放射治疗敏感化。本方法中化合物、盐或溶剂化物的量可根据本文所述的确定所述化合物的有效量的方法进行测定。本发明还涉及抑制哺乳动物中异常细胞生长的方法,其包括一定量的本发明化合物或其可药用盐、溶剂化物、前药或同位素标记的衍生物以及一定量的一种或多种选自抗血管生成剂、信号传导抑制剂和抗增殖性药物。
在实际应用中,根据常规药物配制技术,本发明化合物作为活性成分可以与药用载体结合为紧密混合物。所述载体可根据施用(例如,经口或胃肠外(包括静脉内的))所需的制剂形式而采用多种形式。在制备口服剂型组合物时,可使用任何常规药用介质,例如,水、乙二醇、油类、醇类、矫味剂、防腐剂、着色剂等。在口服液体制剂的情况中,可使用任何常规药用介质,例如,混悬剂、酏剂和溶液剂;或载体例如淀粉、糖、微晶纤维素、稀释剂、成粒剂、润滑剂、粘合剂、崩解剂等。在口服固体制剂情况下,组合物可作为例如粉剂、硬和软胶囊以及片剂形式存在,相对液体剂型来说,优选固体口服剂型。
因为片剂和胶囊容易给药,所以片剂和胶囊代表最有益的口服单位剂型,在此情况下,明显可以采用固体药物载体。如有需要,片剂可通过标准含水或不含水技术包衣。所述组合物和制剂应包含至少0.1%的活性化合物。当然,活性化合物在这些组合物中的百分比可变化,可以有益地在约2%到约60%的单位重量范围内。在所述治疗有用的组合物中的活性化合物的量为能够获得有效剂量的量。活性化合物同样可经鼻内给药,例如,液体滴剂或喷雾剂。
片剂、丸剂、胶囊等可同样包含:粘合剂,例如黄蓍胶、阿拉伯胶、玉米淀粉或明胶;赋形剂,例如磷酸二钙;崩解剂,例如玉米淀粉、土豆淀粉、海藻酸;润滑剂,例如硬脂酸镁;和甜味剂,例如蔗糖、乳糖或糖精。单位剂型为胶囊时,可包含除上述类型材料之外的液体载体,例如脂肪油。
各种不同的其它物质可以作为包衣材料存在,或用于改变单位剂量的物理形式。例如,片剂可用虫胶、糖衣或两者一起包衣。除了活性组分外,糖浆剂或酏剂还可包含:作为甜味剂的蔗糖、作为防腐剂的对羟基苯甲酸甲酯和对羟基苯甲酸丙酯、着色剂和矫味剂(例如樱桃或橙子口味)。
本发明化合物也可以经肠胃外给药。这些活性化合物的溶液或悬浮液可通过在水中与表面活性剂(例如羟基-丙基纤维素)适当地混合来制备。分散液可由甘油、液态聚乙二醇以及其在油中的混合物制备。在储存和使用的常规条件下,这些制剂可以包含防腐剂以防止微生物的生长。
适宜于注射使用的药物形式包括用于即时制备无菌注射溶液或分散体的无菌注射水溶液或分散体和无菌粉末。在所有情况中,该形式必须为无菌的并必须具有足够的流动性使它们易于注射。在制备和储存的情况下,所述形式必须稳定并且必须能够对抗微生物(例如细菌和真菌)的污染。载体可包括溶剂或分散介质,例如水、乙醇、多元醇(例如,甘油、丙二醇和液态聚乙二醇)、其适宜的混合物和植物油。
任何适宜的给药途径可以提供哺乳动物(尤其是人类)有效剂量的本发明化合物。例如,可经口、直肠、局部、肠胃外、眼、肺、鼻等给药。剂型包括片剂、口含片剂、分散剂、混悬剂、溶液剂、胶囊剂、霜剂、软膏剂、气雾剂等。优选本发明化合物经口给药。
施用的活性组分的有效量可取决于该施用的具体化合物、施用模式、待治疗的病症以及待治疗病症的严重性。所述剂量可很容易被本领域技术人员确定。
治疗或预防作为本发明化合物的适应症的癌症、炎症或其它增殖性疾病时,在给予日剂量为约0.01mg到约100mg/kg动物体重时即可以获得大致满意的结果,优选给予单一日剂量。对于大型哺乳动物而言,总的日剂量为约0.1mg到约1000mg,优选为约0.2mg到约50mg。在70kg的成年人情况中,总的日剂量大致为约0.2mg到200mg。所述剂量方案可以调整从而能提供最佳治疗响应。
本发明还涉及药盒(套盒),该药盒包含下列独立包装:
a)有效量的本发明化合物或其生理学可接受的盐、溶剂化物或前药;以及
b)有效量的另外的药物活性成分。
所述药盒包含适当的容器,例如盒子、独立瓶子、袋子或安瓿。药盒可包括例如独立安瓿,每一个含有有效量的本发明化合物和/或其药学上可用的衍生物、溶剂化物和立体异构体(包括其所有比例的混合物)以及溶解形式或冻干形式的有效量的另外的药物活性成分。
具体实施方式
实验部分
在本申请中可能出现的某些缩写如下:
缩写
名称 | |
ACN | 乙腈 |
AcOH | 乙酸 |
AIBN | 偶氮二异丁腈 |
ATP | 三磷酸腺苷 |
b | 宽峰 |
Bop-Cl | 双(2-氧代-3-噁唑烷基)次磷酰氯 |
Conc. | 浓缩 |
d | 双峰 |
DCM | 二氯甲烷 |
DCE | 二氯乙烷 |
DMAP | 二甲氨基吡啶 |
DMF | 二甲基甲酰胺 |
DMSO | 二甲基亚砜 |
DIEA/DIPEA | N,N-二异丙基乙胺 |
DTT | 二硫苏糖醇 |
EDTA | 乙二胺四乙酸 |
equiv./eq. | 当量 |
Et | 乙基 |
h | 小时 |
HEPES | 4-(2-羟基乙基)-1-哌嗪乙磺酸 |
HPLC | 高压液相色谱法 |
LC/MS | 液相色谱法-质谱法 |
LiOH | 氢氧化锂 |
m | 多重峰 |
M | 分子离子 |
m/z | 质荷比 |
Me | 甲基 |
MeOH | 甲醇 |
min | 分钟 |
MS | 质谱法 |
N | 当量(浓度单位) |
NaOH | 氢氧化钠 |
NBS | N-溴代琥珀酰亚胺 |
NMO | 4-甲基吗啉N-氧化物 |
NMP | N-甲基-2-吡咯烷酮 |
NMR | 核磁共振 |
PG | 保护基团 |
psi | 磅/平方英寸 |
q | 四重峰 |
Rf | 保留因子 |
RT/rt | 室温 |
Rt. | 保留时间 |
s | 单峰 |
T3P | 丙基磷酸环酐 |
TBAF | 四丁基氟化铵 |
Tert | 叔 |
TEA | 三乙胺 |
TFA | 三氟乙酸 |
THAB | 四己基溴化铵 |
THF | 四氢呋喃 |
UV | 紫外 |
VIS | 可见 |
本发明化合物可以根据下文流程和实施例中的方法采用适当的物质制备,在下面的具体的实施例中进一步举例说明。
此外,通过使用本文所述方法,结合本领域的常规技术,可容易地制备本文所要求的其它化合物。然而,不能将实施例中说明的化合物理解为是作为本发明的唯一类型。实施例还说明了本发明化合物的制备的详细描述。本领域技术人员容易理解,下列制备方法的条件和过程的已知变通方法能用于制备这些化合物。
本发明化合物通常以其可药用盐形式分离,诸如如上所述的那些。相应于分离的盐的作为游离胺的碱可以用适宜的碱中和制得,所述碱诸如碳酸氢钠、碳酸钠、氢氧化钠和氢氧化钾水溶液,将释放的作为游离胺的碱用有机溶剂萃取,然后蒸发。通过所述方式分离的作为游离胺的可通过将其溶解于有机溶剂中,然后加入适当的酸,最终蒸发、沉淀或结晶而进一步转化为其它可药用的盐。
通过以下流程和实施例中所述的具体实施方案阐述但不限制本发明。除非在流程中另外说明,否则任何变量具有如上所述的同样意义。
除非另外说明,所有的原料来自商业供应商,且未经进一步纯化地使用。除非另外说明,所有的温度以℃表示,且所有的反应在室温进行。化合物通过二氧化硅色谱或制备型HPLC纯化。
本发明还涉及根据下文所述流程和操作实施例制备通式(I)的化合物的方法。
描述中间体和终产物化合物的合成流程
喹唑啉溴化物中间体1a通过商业途径购买的2-氨基-3-甲基苯甲酸根据流程1描述的8步合成法制备。
流程1
喹啉中间体9a、10a通过商业途径购买,11a根据流程2描述的5步合成法制备。
流程2
胺中间体或者通过商业途径购买或者根据以下合成路径(流程3、流程4、流程5和流程6)制备。
流程3
采用Toc保护化合物3a的氨基,得到3b。3b水解后释放出羧酸3c。3c与胺偶联,然后除去Toc保护基,生成胺中间体e。
流程4
芳醛4a与硝基甲烷在碱性条件下反应,得到羟基衍生物4b,在醋酸酐促进的消除条件下将4b转化为烯4c。用N-苄基-1-甲氧基-N-((三甲基硅烷基)甲基)甲胺环化4c,生成吡咯烷衍生物4d。用兰尼镍为催化剂还原4d的硝基,然后通过N-[2-(三甲基硅烷基)乙氧基羰基氧基]琥珀酰亚胺以Teoc保护氨基部分,得到4f。在氢化条件下除去4f的N-苄基并用二碳酸二叔丁酯保护所述N-苄基,得到4h。在四正丁基氟化铵处理后4h中受Teoc保护的伯胺被释放出来,生成胺中间体4i。
流程5
氨基酸5a用Boc保护,得到5b。5b再与胺反应,生成酰胺5c。在氢化条件下除去Cbz基团,生成所希望的胺中间体5d。
流程6
用Teoc选择性地保护氨基酸6a中的氨基,再使酸部分与胺偶联,生成酰胺6c。用TBAF除去Teoc,得到胺中间体6d。
流程7
在还原性胺化条件下,7a和7b反应,生成7c,再用酸处理7c,得到脱保护的吡咯烷中间体7d,为三氟醋酸盐。
流程8
溴化物中间体1a与胺8b偶联,有需要的时候P是保护基,生成8c。在碱性条件下并在过氧化氢的帮助下,腈中间体8c水解,得到酰胺8d,然后去除保护基,得到所希望的化合物8e。
流程9
9a与热的浓硫酸进行氧化水解,将腈转化为羧酰胺9b。9b与羧酸偶联,得到9c。9c脱保护后,得到9d,为所希望的化合物。
流程10
苄基溴化物10a与苯胺9b反应,生成所希望的化合物10b。
流程11
5-溴喹啉-8-腈11a与氨基吡咯烷衍生物在Buckwald Harting偶联反应条件下反应,得到11b。使用热的浓硫酸将腈部分转化为羧酰胺,得到化合物11c。
流程12
在Buckwald Harting偶联反应条件下,5-溴喹啉-8-羧酸甲酯12a与胺中间体8b反应,得到12b。12b用在甲醇中的氨处理,生成羧酰胺12c,脱去12c的保护基,生成12d。
分析方法
使用以下三个方法进行分析性LC/MS:
方法A:使用Discovery C18,5μm,3x30mm柱,流速400μL/分钟,进样环5μL,流动相(A)含0.1%甲酸的水,流动相(B)含0.1%甲酸的甲醇;保留时间以分钟计。方法详述:(I)使用Quaternary Pump G1311A(Agilent),备有UV/VIS二极管阵列检测器G1315B(Agilent)和Finnigan LCQ Duo MS检测器(ESI+模式),UV-检测在254和280nm,梯度:15-95%(B)3.2分钟线性梯度,(II)在95%(B)保持1.4分钟,(III)从95-15%(B)0.1分钟线性梯度,(IV)在15%(B)保持2.3分钟。
方法B:使用Waters Symmetry C18,3.5μm,4.6x75mm柱,流速1mL/分钟,进样环10μL,流动相(A)为含0.05%TFA的水,流动相(B)为含0.05%TFA的ACN;保留时间以分钟计。方法详述:(I)使用Binary Pump G1312A(Agilent),备有UV/Vis二极管阵列检测器G1315B(Agilent)和Agilent G1956B(SL)MS检测器(ESI+模式),UV-检测在254和280nm,梯度:20-85%(B)10分钟线性梯度,(II)在85%(B)保持1分钟,(III)从85-20%(B)0.2分钟线性梯度,(IV)在20%(B)保持3.8分钟。
方法C:梯度:4.2分钟/流速:2ml/分钟99:01-0:100水+0.1%(体积)TFA;乙腈+0.1%(体积)TFA;0.0至0.2分钟:99:01;0.2至3.8分钟:99:01→0:100;3.8至4.2分钟:0:100;柱:Chromolith Performance RP18e;长度100mm,直径3mm;波长:220nm。
分析型手性HPLC
使用来自Daicel Chemical Industries,Ltd.的手性Pak AD-H柱(250X4.6mm)在Agilent1100系列系统进行分析型手性HPLC。该方法使用5.0μL进样体积,流速1mL/分钟,使用100%甲醇在25℃运行15分钟,且UV-检测在254和280nm。
制备型HPLC
使用Waters Atlantis dC18OBD TM10μM(30X250mm)柱或Waters Sunfire PrepC18OBD10μM(30X250mm)柱进行制备型HPLC。所述柱在装备有进样环(10mL)和ISCOUA-6UV/Vis检测器的Waters Prep LC4000System以60mL/分钟的流速使用。流动相从含有(A)水和(B)HPLC-级乙腈的两个溶剂瓶中吸入。通常的制备使用线性梯度(例如,0-60%溶剂B经历60分钟)。
实施例
以下操作实施例旨在阐明本发明的具体实施方案,并不意欲以任何方式限制说明书或权利要求的范围。这些操作实施例描述一些试剂(用来制备治疗过度增殖性疾病的杂环羧酰胺化合物)的合成方法以及描述这些杂环喹唑啉和喹啉羧酰胺化合物的合成方法。
中间体的制备
中间体A:5-溴喹唑啉-8-腈
步骤1:8-甲基喹唑啉-4(3H)-酮
2-氨基-3-甲基苯甲酸(100g,0.66mol)、醋酸甲脒(206g,1.98mol)和甲酰胺(26mL,0.6600mol)混合在一起放在配有机械搅拌器的2L圆底烧瓶中。反应混合物在160℃加热16小时。通过LCMS监测反应是否完成。待反应完成后,将反应混合物冷却至室温,用2NNaOH溶液(300mL)稀释。在同一温度下搅拌15分钟,用1.5N HCl溶液中和反应混合物。滤出固体沉淀物,用冰冻水洗涤,真空干燥,得到标题化合物(90g,86%得率),为乳白色固体。1HNMR(DMSO-d6,400MHz)δ12.21(bs,1H),8.10(s,1H),7.95-7.93(dd,J=8.8,7.9Hz,1H),7.65-7.63(d,J=7.9Hz,1H),7.39-7.35(t,J=15.2Hz,1H),2.51(s,3H)。
步骤2:4-氯-8-甲基喹唑啉
在氮气气氛下将POCl3(300mL)放在2L圆底烧瓶中。分批加入8-甲基喹唑啉-4(3H)-酮(45g)。反应混合物在120℃回流12小时。通过TLC和LCMS监测反应是否完成。待反应完成后,将反应混合物冷却至室温并减压蒸干。得到的残留物溶解在DCM(500mL)中,在恒定搅拌速度下倒入冰冻的饱和K2CO3溶液中。分离有机层,用盐水溶液洗涤,硫酸钠干燥,真空浓缩,得到(45g,90%得率)标题化合物,为黄色固体。该化合物用在下一步骤中,无需进一步纯化。1H NMR(CDCl3,400MHz)δ9.03(s,1H),8.08-8.06(dd,J=8.9,8.4Hz,1H),7.77-7.76(d,J=7.1Hz,1H),7.59-7.56(d,J=15.5Hz,1H),2.75(s,3H)。
步骤3:8-甲基喹唑啉
在氮气气氛下,边搅拌边向4-氯-8-甲基喹唑啉(45g,0.252mol)在DCM(700mL)中的溶液分批加入对甲苯磺酰肼(65.9g,0.353mol)。反应混合物在45℃加热12小时。通过TLC和LCMS监测反应是否完成。待反应完成后,将反应混合物冷却至室温,溶剂蒸干。得到的残留物溶解在乙醇(500mL)中,加入2N NaOH溶液(300mL),回流6小时。经LCMS确认后,反应混合物冷却至室温,用MTBE(3x600mL)萃取。有机层合并,用盐水溶液洗涤,硫酸钠干燥,真空浓缩。获得的残留物通过柱色谱法过滤,使用中和的硅胶(60-120目)和石油醚/乙酸乙酯为洗脱液,得到(15g,27%得率)标题化合物,为低溶点黄色固体。1H NMR(DMSO-d6,400MHz)δ9.54(s,1H),9.31(s,1H),7.97-7.94(dd,J=8.8,8.1Hz,1H),7.87-7.84(m,1H),7.65-7.62(d,J=15.2Hz,1H),2.67(s,3H)。
步骤4:5-溴-8-甲基喹唑啉
0℃下分批向8-甲基喹唑啉(10g,0.0694mol)在浓H2SO4(100mL)中的溶液加入硫酸银(34.64g,0.1111mol)。再滴加入溴(4.4mL,0.0832mol)。反应混合物室温搅拌16小时。定期地通过LCMS监测反应。16小时后,LCMS显示有42%起始材料和51%产物。向反应混合物加入冰,用NH4OH溶液碱化。水层用乙酸乙酯(4x500mL)萃取,水和盐水溶液洗涤。有机层用Na2SO4干燥,真空浓缩。粗产物通过柱色谱法纯化,使用中和的硅胶(60-120目)和石油醚/乙酸乙酯为洗脱液,得到(51%得率)标题化合物,为浅黄色液体。1H NMR(DMSO-d6,400MHz)δ9.60-9.58(s,1H),9.40-9.38(s,1H),7.93-7.91(d,J=7.72Hz,1H),7.77-7.75(d,J=7.72Hz,1H),2.62(s,3H)。
步骤5:5-溴-8-(二溴甲基)喹唑啉
在氮气气氛下,边搅拌边向5-溴-8-甲基喹唑啉(46g,0.206mol)在CCl4(800mL)中的溶液加入N-溴琥珀酰亚胺(80.4g,0.451mol),再在室温加入AIBN(6.74g,0.041mol)。反应混合物在90℃加热12小时。后反应完成后,反应混合物冷却至室温,滤出,并用CCl4洗涤。滤液浓缩至干,得到(61g)标题化合物,为黄色液体。粗产物用在下一步骤中,无需纯化。1HNMR(DMSO-d6,400MHz)δ9.73(s,1H),9.53(s,1H),8.45-8.43(d,J=8.04Hz,1H),8.22-8.20(d,J=8.04Hz,1H),8.02(s,1H)。
步骤6:5-溴喹唑啉-8-甲醛
0℃下边搅拌边向5-溴-8-(二溴甲基)喹唑啉(61g,粗混合物)在丙酮(500mL)和水(100mL)中的溶液分批加入硝酸银(61g)。反应混合物室温搅拌6小时。通过TLC确认反应完成。滤出反应混合物,滤液用乙酸乙酯(3x500mL)萃取。有机层用10%NaHCO3溶液、水和盐水溶液洗涤。溶剂用Na2SO4干燥,真空浓缩,得到的粗产物用HPLC纯化(56%)(25g,65%),制备型HPLC条件:柱:Xterra,C18(19X300mm),10微米,流动相:0.1%TFA;B:甲醇,以分离出化合物。得到的固体用NH4OH碱化,乙酸乙酯萃取。有机层用水洗涤。溶剂用Na2SO4干燥,真空浓缩,得到(6.2g)标题化合物,为浅黄色固体。1H NMR(DMSO-d6,400MHz)11.14(s,1H),9.80(s,1H),9.58(s,1H),8.30-8.27(d,J=12.3Hz,2H)。
步骤7:5-溴-喹唑啉-8-甲醛肟
向5-溴-喹唑啉-8-甲醛(2400.00mg;10.12mmol;1.00eq.)在乙腈(10ml)中的悬液加入羟胺氯化氢(773.90mg;11.14mmol;1.10eq.),再加入三乙胺(1.57ml;11.14mmol;1.10eq.)。反应混合物在100℃搅拌1小时,LCMS显示MS270/272(M+18)。反应混合物冷却,过滤,滤液用醚洗涤,收集产物5-溴-喹唑啉-8-甲醛肟3000mg,得率117%(1HNMR显示含有1eq三乙胺盐酸盐)。
步骤8:5-溴喹唑啉-8-腈
向5-溴-喹唑啉-8-甲醛肟(3000.00mg;11.90mmol;1.00eq.)在DMF(15ml)中的溶液加入2,4,6-三丙基-[1,3,5,2,4,6]三氧杂三磷杂环己烷2,4,6三氧化物(10.42ml;17.85mmol;1.50eq.)在DMF中的50%溶液。得到的混合物在100℃搅拌45分钟,LCMS显示主峰(MS:252/254,234/236)和小峰(MS:208/209)。反应混合物冷却,倒入水中,用乙酸乙酯萃取,干燥,浓缩,得到粘性固体,该固体用醚洗涤,收集到标题产物(1665mg.得率59.6%)。LC-MS(232/234and250/252)。
中间体B:5-溴喹啉-8-羧酸甲酯
步骤1:5-溴-8-甲基喹啉
0℃下向8-甲基喹啉(30g,0.209mol)在浓H2SO4(300ml)中的溶液分批加入硫酸银(97.98g,0.314mol),再滴加入溴(10.74ml,0.209mol)。待溴的加入完成后,反应混合物室温搅拌4小时,通过TLC确认反应是否完成。待反应完成后,向反应混合物加入冰,用NH4OH溶液碱化,乙酸乙酯萃取。有机层用水、盐水溶液洗涤,无水硫酸钠干燥,浓缩,得到(43g,92.4%得率)深褐色液体。粗产物无需纯化可用在下一步骤。1H NMR(DMSO-d6,400MHz):δ8.97-8.96(dd,J=4.16,5.8Hz,1H),8.45-8.42(dd,J=8.56,10.2Hz,1H),7.81-7.79(d,J=7.68Hz,1H),7.67-7.64(dd,J~8.52,12.64Hz,1H),7.53-7.51(dd,J=7.64,8.52Hz,1H),2.66(s,3H)。
步骤2:5-溴-8-(二溴甲基)喹啉
室温下向5-溴-8-甲基喹啉(86g,0.387mol)在CCl4(700ml)中的溶液加入N-溴琥珀酰胺(144g,0.813mol),再加入过氧化苯甲酰(8.6g),反应混合物在90℃加热12小时。通过TLC确认反应是否完成。待反应完成后,滤出反应混合物,浓缩,得到(140g,95%得率)浅橙色固体,粗产物无需纯化可用在下一步骤。1H NMR(DMSO-d6,400MHz):δ9.1-9.08(dd,J=4.16,5.8Hz,1H),8.59-8.57(dd,J=8.56,10.2Hz,1H),8.25-8.23(d,J=8.04Hz,1H),8.16-8.11(t,J=19.08Hz,2H),7.82-7.79(dd,J=8.6,12.8Hz,1H)。
步骤3:5-溴喹啉-8-甲醛
0℃下10分钟内向5-溴-8-(二溴甲基)喹啉(75g,0.197mol)在丙酮(400mL)和水(100mL)中的溶液分批加入硝酸银(75g)。反应混合物室温搅拌6小时。通过TLC确认反应是否完成。待反应完成后,滤出反应混合物,滤液用MTBE(1000ml)萃取。有机层用10%NaHCO3溶液、水和盐水溶液洗涤。有机层用Na2SO4干燥,浓缩,得到(15g,32%得率)标题化合物,为白色固体。1H NMR(DMSO-d6,400MHz):δ11.272-11.27(s,1H),9.17-9.15(dd,J=4.2,5.8Hz,1H),8.64-8.62(dd,J=8.6,10.3Hz,1H),8.17-8.15(d,J=7.84,1H),8.09-8.07(d,J=7.88Hz,1H),7.85-7.82(dd,J=8.64,12.84Hz,1H)。
步骤4:5-溴喹啉-8-羧酸
室温下10分钟内向5-溴喹啉-8-甲醛(10g,0.039mol)在THF(300ml)中的溶液分批加入NaOH(30g)水溶液,再加入硝酸银(10.79g,0.0635mol),该反应混合物室温搅拌30分钟。通过TLC确认反应是否完成。待反应完成后,滤出反应混合物。黑色固体用THF、甲醇和DMF(各50ml)洗涤。(注:产物在上述任一种溶剂中都不溶解,弃掉滤液和洗涤液)。黑色固体干燥,得到标题化合物(粗产物-30g)。粗产物无需纯化可用在下一步骤。1H NMR(DMSO-d6,400MHz):δ8.92-8.91(dd,J=4.12,5.8Hz,1H),8.49(s,1H),8.46-8.44(dd,J=8.56,10.2Hz,1H),7.83-7.81(dd,J=7.6,Hz,1H),7.63-7.6(dd,J=8.52,12.68Hz,1H),7.46-7.44(d,J=7.6Hz,1H)。
步骤5:5-溴喹啉-8-羧酸甲酯
室温下向5-溴喹啉-8-羧酸(30g,0.119mol,未纯化)在DMF(400ml)中的溶液加入碳酸钾(41.12g,0.297mol)和碘甲烷(MeI)(22.3ml,0.357mol)。反应混合物室温搅拌12小时,通过TLC确认反应是否完成。待反应完成后,滤出反应混合物并蒸发。反应混合物用10%NaHCO3碱化,并用乙酸乙酯萃取。有机层用水和盐水洗涤,硫酸钠干燥,浓缩,得到标题化合,为褐色液体(4.6g)。LCMS:实测值(M+,268)。1H NMR(DMSO-d6,400MHz):δ9.04-9.02(dd,J=3.92,5.68,Hz,1H),8.58-8.56(m,1H),8.05-8.03(d,J=7.72Hz,1H),7.87-7.86(d,J=7.76Hz,1H),7.78-7.75(dd,J=8.6,12.8Hz,1H),3.91(s,3H)。
中间体C的代表性合成(流程4)
3-氨基-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式,外消旋物)
步骤1:1-(3-三氟甲氧基-苯基)-2-硝基-乙醇
3-氟甲氧基苯甲醛(21.37ml;201.43mmol;1.00eq.)和硝基甲烷(13.06ml;241.71mmol;1.20eq.)在甲醇(40ml)中的溶液冷却至-10℃。10分钟内加入NaOH(8.46g;211.50mmol;1.05eq.)在水(20ml)中的溶液,保持温度低于-5℃。反应混合物在-5℃搅拌15分钟,在搅拌期间反应溶液固化为白色固体。反应混合物的温度升至0℃,用水(150ml)稀释。在全部固体溶解之后,加入HCl(4M,100ml)。反应混合物用DCM(300ml x2)萃取。萃取液合并,用盐水洗涤,浓缩,得到所希望的1-(3-三氟甲氧基-苯基)-2-硝基-乙醇34.8g,得率是93%。
步骤2:1-三氟甲氧基-3-((E)-2-硝基-乙烯基)-苯
0℃下将N,N-二甲基吡啶-4-胺(2.30g;18.80mmol)加入1-(3-氟甲氧基苯基)-2-硝基乙醇(34.80g;187.95mmol)在醋酸酐(35.53ml;375.90mmol)中的溶液中,室温搅拌72小时。将反应混合物倒入强烈搅拌下的NaHCO3饱和溶液(400mL)中。所希望的中间体用乙酸乙酯(3x100mL)萃取。有机萃取液用饱和NaHCO3溶液、盐水洗涤,MgSO4干燥,过滤,浓缩,得到所希望的1-三氟甲氧基-3-((E)-2-硝基-乙烯基)-苯26.0g,得率为83%。
步骤3:反-1-苄基-3-(3-三氟甲氧基-苯基)-4-硝基-吡咯烷
将N-苄基-1-甲氧基-N-[(三甲基硅烷基)甲基]甲胺加入1-三氟甲氧基-3-((E)-2-硝基-乙烯基)-苯(6.00g;35.90mmol)在DCM(50ml)中的溶液中。反应溶液冷却至0℃,滴加入TFA(0.30ml;3.95mmol),室温搅拌过夜。反应溶液用水和盐水洗涤,MgSO4干燥,过滤,以及浓缩。粗材料经Biotage(340g柱)纯化,洗脱液为5%乙酸乙酯在己烷中的溶液,得到所希望的产物5.5g,得率为51%。
步骤4:(反-1-苄基-4-(3-三氟甲氧基-苯基)-吡咯烷-3-基胺
将反-1-苄基-3-(3-三氟甲氧基苯基)-4-硝基吡咯烷(5.50g;18.31mmol)溶解在甲醇(300mL)中。加入NH3(30ml,2.0M在甲醇中的溶液),使溶液通过H cube反应器(流速1.5min/min,全氢,50℃)。反应溶液浓缩,得到(反-1-苄基-4-(3-三氟甲氧基-苯基)-吡咯烷-3-基胺4.6g,得率为92%。
步骤5:2-(三甲基硅烷基)乙基[反-1-苄基-4-(3-三氟甲氧基-苯基)-吡咯烷-3-基]-氨基甲酸酯
0℃下将1-({[2-(三甲基硅烷基)乙氧基]羰基}氧基)吡咯烷-2,5-二酮(4.5g;17.37mmol)加入反-1-苄基-4-(3-三氟甲氧基苯基)吡咯烷基-3-胺(4.5g;16.87mmol)和DIEA(4.5ml;25.30mmol)在DCM(50ml)中的溶液中。反应混合物再加热至室温,并在室温下搅拌1小时。反应溶液用盐水洗涤,MgSO4干燥,过滤,浓缩。粗材料经Biotage纯化,洗脱液为梯度30%至60%乙酸乙酯在己烷中的溶液,得到标题化合物6.0g,得率为99%。
步骤6:2-(三甲基硅烷基)乙基[反-4-(3-三氟甲氧基-苯基)-吡咯烷-3-基]--氨基甲酸酯
将乙酸(2mL)加入2-(三甲基硅烷基)乙基[反-苄基-4-(3-三氟甲氧基苯基)吡咯烷-3-基]氨基甲酸酯(2.50g;6.03mmol)在乙醇(150ml)中的溶液。再加入Pd/C(1.25g,wet,10%Pd),将反应混合置于物parr shaker装置(压力60Psi)中,反应2小时。滤出反应混合物,滤液浓缩,得到标题化合物(1.96g,定量得率)。
步骤7:反-3-(3-三氟甲氧基苯基)-4-({[2-(三甲基硅烷基)乙氧基]羰基}氨基)-吡咯烷-1-羧酸叔丁酯
将二碳酸二叔丁酯(1.27g;5.82mmol)加入2-(三甲基硅烷基)乙基[反-4-(3-氟甲氧基苯基)吡咯烷-3-基]氨基甲酸酯(1.80g;5.55mmol)和DIEA(2.2ml;12.26mmol)在DCM(100ml)中的溶液中,室温搅拌过夜。反应混合物浓缩,粗产物经Biotage纯化,洗脱液为梯度20%至60%乙酸乙酯在己烷中的溶液,得到标题化合物2.0g,得率为85%。
步骤8:3-氨基-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式,外消旋物)
反-3-(3-三氟甲氧基苯基)-4-({[2-(三甲基硅烷基)乙氧基]羰基}氨基)-吡咯烷-1-羧酸叔丁酯(2.4g;5.76mmol)和N,N,N-三丁基丁烷-1-氟化铵(20.00ml;1.00M;20.00mmol)溶解在甲醇中,室温搅拌过夜。粗产物经Biotage纯化,洗脱液为梯度5%至10%甲醇在DCM中的溶液,得到标题化合物(1.61g,得率79%)。LC-MS(M+H=346,obsd=347)。1HNMR(DMSO-d6)δ1.39(s,9H),1.55(s,1H),2.90-2.99(m,2H),3.24-3.26(m,1H),3.33-3.37(m,1H),3.55-3.57(m,1H),3.60-3.68(m,1H),3.70-3.72(m,1H),7.05-7.06(m,1H),7.13-7.15(m,2H),7.35-7.36(m,1H)。
中间体D的代表性合成(流程6)
((3-(苯基氨基甲酰基)哌啶-3-基)甲基)氨基甲酸苄酯(外消旋物)
步骤1:3-((((苄基氧基)羰基)氨基)甲基)-1-((2-(三甲基硅烷基)乙氧基)-羰基)哌啶-3-羧酸
向3-(苄基氧基羰基氨基-甲基)-哌啶-3-羧酸盐酸盐(2000.00mg;6.08mmol;1.00eq.)在DME(60ml)中的溶液加入DIEA(3.82ml;21.29mmol;3.50eq.)。搅拌15分钟后,加入3-三甲基硅烷基-丙酸2,5-二氧代-吡咯烷-1-基酯(1628.18mg;6.69mmol;1.10eq.)。反应混合物室温搅拌过夜。向反应溶液另外加入50ml DME,再用1%柠檬酸、盐水洗涤,干燥,浓缩,得到残留物,显示干净质谱峰为标题化合物(2462mg,得率85%),该化合物直接用于下一步骤反应。
步骤2:2-(三甲基硅烷基)乙基3-((((苄基氧基)羰基)氨基)甲基)-3-(苯基氨基甲酰基)哌啶-1-羧酸酯
向3-((((苄基氧基)羰基)氨基)甲基)-1-((2-(三甲基硅烷基)乙氧基)羰基)哌啶-3-羧酸(2462.00mg;5.64mmol;1.00eq.)在DCE(4.0ml)中的溶液加入双(2-氧代-1,3-噁唑烷-3-基)次磷酰氯(1435.59mg;5.64mmol;1.00eq.)。室温搅拌15分钟后,加入DIEA(1.52ml;8.46mmol;1.50eq.)和苯基胺(525.18mg;5.64mmol;1.00eq.)。反应混合物室温搅拌过夜。向反应混合物加入50ml DCM,用盐水洗涤,干燥,浓缩。残留物用SNAP柱(100g)纯化,洗脱液为20-50%乙酸乙酯在己烷中的溶液,得到标题化合物(2600mg,得率90.1%)。
步骤3:((3-(苯基氨基甲酰基)哌啶-3-基)甲基)氨基甲酸苄酯
2-(三甲基硅烷基)乙基3-((((苄基氧基)羰基)氨基)甲基)-3-(苯基氨基甲酰基)哌啶-1-羧酸酯(1200.00mg;2.35mmol;1.00eq.)与TBAF(10.00ml;9.38mmol;4.00eq.)在THF中的反应混合物室温搅拌过夜。粗产物经制备型HPLC纯化,得到标题化合物(600mg,69.6%)。
中间体E的代表性合成(流程5)
3-氨基甲基-3-苯基氨基甲酰基-吡咯烷-1-羧酸叔丁酯(外消旋物)
步骤1:3-(苄基氧基羰基氨基-甲基)-吡咯烷-1,3-二羧酸1-叔丁酯
3-(苄基氧基羰基氨基-甲基)-吡咯烷-3-羧酸盐酸盐(2000.00mg;6.35mmol;1.00eq.)和二碳酸二叔丁酯(1.77ml;8.26mmol;1.30eq.)的反应混合物悬于正丁醇(25.00ml)中,再用2N NaOH水溶液(3.97ml;7.94mmol;1.25eq.)处理。反应混合物加热至75℃(马上观察到有冒泡),加热2小时。反应混合物浓缩。残留物溶解在乙酸乙酯(100ml)中,用水和盐水洗涤,MgSO4干燥,浓缩,干燥,得到3-(苄基氧基羰基氨基-甲基)-吡咯烷-1,3-二羧酸1-叔丁酯(2200mg,89.4%)。
步骤2:3-(苄基氧基羰基氨基-甲基)-3-苯基氨基甲酰基-吡咯烷-1-羧酸叔丁酯
向3-(苄基氧基羰基氨基-甲基)-吡咯烷-1,3-二羧酸1-叔丁酯(2200.00mg;5.81mmol;1.00eq.)在DCE(40.0ml)中的溶液加入双(2-氧代-1,3-噁唑烷-3-基)次磷酰氯(1627.95mg;6.40mmol;1.10eq.)。搅拌15分钟后,加入DIEA(1.25ml;6.98mmol;1.20eq.)和苯基胺(595.55mg;6.40mmol;1.10eq)。反应混合物室温搅拌过夜。加入50ml DCM。溶液用盐水洗涤,干燥,浓缩,得到粗产物,该粗产物用biotage纯化,洗脱液为20-50%乙酸乙酯在己烷中的溶液,得到标题化合物(1800mg,68.3%)。
步骤3:3-氨基甲基-3-苯基氨基甲酰基-吡咯烷-1-羧酸叔丁酯
向3-(苄基氧基羰基氨基-甲基)-3-苯基氨基甲酰基-吡咯烷-1-羧酸叔丁酯(1200.00mg;2.65mmol;1.00eq.)在30ml甲醇中的溶液加入甲酸铵(1668.40mg;26.46mmol;10.00eq.)和10%Pd/C(湿润)1.2g。混合物在65℃搅拌1小时,然后过滤,浓缩,得到粗产物,该粗产物溶解在DCM中,用5%NaHCO3、盐水洗涤,干燥,浓缩,得到标题化合物(820mg,97%)。
中间体F的代表性合成(流程3)
3-氨基-4-((3-氟苯基)氨基甲酰基)吡咯烷-1-羧酸叔丁酯(外消旋物)
步骤1:4-(2-三甲基硅烷基-乙氧基羰基氨基)-吡咯烷-1,3-二羧酸1-叔丁酯3-乙酯
4-(2-三甲基硅烷基-乙氧基羰基氨基)-吡咯烷-1,3-二羧酸1-叔丁酯3-乙酯(4443.00mg;11.04mmol;1.00eq.)、LiOH.H2O(1389.45mg;33.11mmol;3.00eq.)在水(16.50ml)和甲醇(16.50ml)中的反应混合物在45℃搅拌过夜。移除部分溶剂后,混合物用DCM萃取,用5%柠檬酸洗涤,干燥,浓缩,得到浅黄色油,为标题化合物(3200mg,77.4%)。
步骤2:3-(3-氟-苯基氨基甲酰基)-4-(2-三甲基硅烷基-乙氧基羰基氨基)-吡咯烷-1-羧酸叔丁酯
向4-(2-三甲基硅烷基-乙氧基羰基氨基)-吡咯烷-1,3-二羧酸1-叔丁酯(3200.00mg;8.54mmol;1.00eq.)在DCE(40.0ml)中的溶液加入双(2-氧代-1,3-噁唑烷-3-基)次磷酰氯(2392.68mg;9.40mmol;1.10eq.)。搅拌15分钟后,加入DIEA(1.69ml;9.40mmol;1.10eq.)和3-氟-苯基胺(1044.40mg;9.40mmol;1.10eq)。反应混合物在45℃搅拌过夜。反应溶液用乙酸乙酯稀释,洗涤,干燥,浓缩,得到粗产物,该粗产物用SNAP(100g)柱纯化(洗脱液为20-50%乙酸乙酯在己烷中的溶液),得到标题化合物(1700mg,42.5%)。
步骤3:3-氨基-4-(3-氟-苯基氨基甲酰基)-吡咯烷-1-羧酸叔丁酯
向3-(3-氟-苯基氨基甲酰基)-4-(2-三甲基硅烷基-乙氧基羰基氨基)-吡咯烷-1-羧酸叔丁酯(1700.00mg;3.64mmol;1.00eq.)加入TBAF(2851.67mg;10.91mmol;3.00eq.)(1.0M in THF11ml)。得到的混合物搅拌过夜。将反应混合物倒入水中,用盐水、5%NaHCO3、盐水洗涤,干燥,浓缩,得到粗产物,向该粗产物加入醚(5ml)。滤出白色沉淀固体,得到标题化合物(710mg,60.4%)。
中间体G的代表性合成(流程7)
N-(3,4-二氯苄基)吡咯烷-3-胺(外消旋物)
步骤1:3-((3,4-二氯苄基)氨基)吡咯烷-1-羧酸叔丁酯
3-氨基吡咯烷-1-羧酸叔丁酯(1.5g;8.05mmol;1.00eq.)和3,4-二氯苯甲醛(1339.00mg;7.65mmol;0.95eq.)在甲醇(10.00ml)和乙酸(1.00ml)中的溶液室温搅拌30分钟,再加入氰基硼氢化钠(9.66ml;9.66mmol;1.20eq.)。反应混合物室温搅拌多2小时,在搅拌期间,向反应混合物倒入氨水溶液(30mL)。滤出得到的无机沉淀物,用二氯甲烷(50mL)洗涤。分离出有机层,剩下的水层用二氯甲烷(50mL x3)萃取。有机萃取液合并,用盐水(50mL)洗涤,硫酸钠干燥,过滤,真空浓缩。得到的油经快速硅柱色谱法纯化,洗脱液为乙酸乙酯在己烷中的梯度溶液,得到所希望的中间体3-((3,4-二氯苄基)氨基)吡咯烷-1-羧酸叔丁酯(2.47g;7.16mmol;88.9%),为澄清粘性油。LC-MS(M+H=346,obsd.=288(M-57))。
步骤2:N-(3,4-二氯苄基)吡咯烷-3-胺
向3-((3,4-二氯苄基)氨基)吡咯烷-1-羧酸叔丁酯(100mg;0.29mmol;1.00eq)在二氯甲烷(3mL)中的溶液加入三氟乙酸(0.04mL;0.58mmol;2.00eq)。反应烧瓶配有氩气入口,搅拌至TLC确认反应完成(10%甲醇在二氯甲烷中的溶液)。反应完成后,真空浓缩溶液,得到干的残留物,再溶解在二氯甲烷中,浓缩(x3),得到所希望的中间体G,为TFA盐,定量得率。LC-MS(M+H=246,obsd.=246)。
通式(I)的实施例化合物
实施例1 5-((4-(4-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(反式_外消旋物)
步骤1:3-((8-氰基-喹唑啉-5-基)氨基)-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)
中间体A(100.00mg;0.43mmol;1.00eq.)、3-氨基-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)(155.38mg;0.45mmol;1.05eq.)和DIEA(0.15ml;0.85mmol;2.00eq.)在NMP(2ml)中的反应混合物在120℃搅拌过夜。反应混合物经制备型HPLC纯化,得到标题化合物(120mg,56.8%)。
步骤2:3-((8-氨基甲酰基喹唑啉-5-基)氨基)-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)
3-(8-氰基-喹唑啉-5-基氨基)-4-(4-三氟甲氧基-苯基)-吡咯烷-1-羧酸叔丁酯(100.00mg;0.20mmol;1.00eq.)与2.0M NaOH水溶液(1ml;2.00mmol;10.00eq.)以及35%H2O2水溶液(0.19ml;2.00mmol;10.00eq.)在DMSO(8ml)中于40℃搅拌过夜。粗产物经制备型HPLC纯化,得到标题化合物(58mg,56.0%)。
步骤3:5-((4-(4-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(反式_外消旋物)
向3-((8-氨基甲酰基喹唑啉-5-基)氨基)-4-(4-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)58.0mg加入1ml甲醇、1ml4.0M HCl在二噁烷中的溶液。得到的混合物室温搅拌3小时。移除溶剂,得到粗产物,该粗产物用乙腈处理,得到实施例1(42mg),为盐酸盐。LC-MS(M+H=418,obsd.=418)。1HNMR:(DMSO)10.12(s,1H),9.80(s,1H),9.67(s,1H),9.32(1s,1H),8.49-8.51(d,2H),8.05-8.07(d,1H),7.67-7.70(d,2H),7.38-7.40(d,2H),6.72-6.7(d,1H),4.65(t,1H),3.77-3.81(m,3H),3.35-3.40(m,1H),3.15-3.25(m,1H),3.20(s,1H)。
P70S6K IC50:23nM
实施例2 5-((4-(3-氯-5-氟苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(反式_外消旋物)
通过与3-氨基-4-(3-氯-5-氟苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=386,obsd.=386/388)。
P70S6K IC50:160nM
实施例3 5-((4-苯基哌啶-3-基)氨基)喹唑啉-8-羧酰胺(反式_外消旋物)
通过与3-氨基-4-苯基哌啶-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=348,obsd=348)。
P70S6K IC50:4.1nM
实施例4 5-((4-(3-氟-4-(三氟甲基)苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(反式_外消旋物)
通过与3-氨基-4-(3-氟-4-(三氟甲基)苯基)哌啶-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=434,obsd.=434)。1HNMR:(DMSO)9.85(s,1H),9.20(s,1H),9.24-9.26(d,2H),8.50-8.52(d,1H),7.73-7.75(m,1H),7.47-7.49(d,1H),7.29-7.30(d,1H),6.88-6.90(d,1H),4.50-4.55(d,1H),3.58-3.60(m,1H),3.46-3.49(m,1H),3.35-3.40(m,2H),3.12-3.14(m,1H),2.80-2.84(m,1H),2.30-2.35(m,1H)。
P70S6K IC50:5.9nM
实施例5 5-(((3R)-4-(3-氟-4-(三氟甲基)苯基)哌啶-3-基)氨基)喹唑啉-8-羧 酰胺(手性,实施例4的对映异构体之一,不知道绝对构型)
通过手性色谱法从实施例4分离出标题化合物。LC-MS(M+H=434,obsd.=434)。
P70S6K IC50:9.9nM
实施例6 5-(((3S,4S)-4-(3-氟-4-(三氟甲基)苯基)哌啶-3-基)氨基)喹唑啉-8- 羧酰胺(手性,实施例4的第二个对映异构体,不知道绝对构型)
通过手性色谱法从实施例4分离出标题化合物。LC-MS(M+H=434,obsd.=434)。
P70S6K IC50:54nM
实施例7 (S)-5-((1-(3-氟苯基)-2-(甲基氨基)乙基)氨基)喹唑啉-8-羧酰胺(手 性)
中间体A(100.00mg;0.43mmol;1.00eq.)、N-[(S)-2-氨基-2-(3-氟-苯基)-乙基]-4-硝基-苯磺酰胺(152.24mg;0.45mmol;1.05eq.)和DIEA(0.15ml;0.85mmol;2.00eq.)在NMP(1ml)中的反应混合物在120℃搅拌过夜。反应溶液冷却,再被倒入水中,用乙酸乙酯萃取,用盐水洗涤,干燥,浓缩,得到粗产物,该粗产物经SNAP柱(25g,洗脱液为20-80%乙酸乙酯在己烷中的溶液)纯化,得到N-[(S)-2-(8-氰基-喹唑啉-5-基氨基)-2-(3-氟-苯基)-乙基]-N-甲基-4-硝基-苯磺酰胺(120mg)。
边搅拌边向N-[(S)-2-(8-氰基-喹唑啉-5-基氨基)-2-(3-氟-苯基)-乙基]-N-甲基-4-硝基-苯磺酰胺(120.00mg;0.24mmol;1.00eq.)在DMSO(8ml)中的溶液加入2.0M NaOH水溶液(0.59ml;1.18mmol;5.00eq.)和35%过氧化氢水溶液(0.14ml;1.42mmol;6.00eq.),40℃下继续搅拌过夜。粗产物经制备型HPLC纯化,得到所希望的产物,向该产物加入乙腈(2ml)、苯硫酚(0.1ml)、CsCO3(200mg),40℃下搅拌过夜。粗产物经制备型HPLC纯化,得到标题产物。LC-MS(M+H=434,obsd.=434)。
P70S6K IC50:>1000nM
实施例8 5-(4-(2-氨基-1-(4-(三氟甲基)苯基)乙基)哌嗪-1-基)喹唑啉-8-羧酰 胺(外消旋物)
通过与4-硝基-N-(2-(哌嗪-1-基)-2-(4-(三氟甲基)苯基)乙基)苯磺酰胺进行偶联反应,再进行水解和脱保护,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=445,obsd=445)。
P70S6K IC50:210nM
实施例9 5-(3-氨基-3-((2,4-二氟苯甲酰氨基)甲基)吡咯烷-1-基)喹唑啉-8-羧 酰胺(外消旋物)
通过与N-((3-氨基吡咯烷-3-基)甲基)-2,4-二氟苯甲酰胺进行偶联反应,再进行腈水解,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=427,obsd=427)。
p70S6K IC50:>1000nM
实施例10 5-(3-氨基-3-((4-氟-2-羟基苯甲酰氨基)甲基)吡咯烷-1-基)喹唑啉- 8-羧酰胺(外消旋物)
合成实施例9的副产物被分离出来就是标题化合物。LC-MS(M+H=425,obsd=425)。
p70S6K IC50:>1000nM
实施例11 5-(3-(氨基甲基)-3-(苯基氨基甲酰基)哌啶-1-基)喹唑啉-8-羧酰胺 (外消旋物)
通过与((3-(苯基氨基甲酰基)哌啶-3-基)甲基)氨基甲酸苄酯进行偶联反应,再进行水解和脱保护,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=404,obsd=405)。
p70S6K IC50:>1000nM
实施例12 5-(((3-(苯基氨基甲酰基)吡咯烷-3-基)甲基)氨基)喹唑啉-8-羧酰胺 (外消旋物)
通过与3-(氨基甲基)-3-(苯基-氨基甲酰基)吡咯烷-1-羧酸叔丁酯(外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=390,obsd.=391)。
p70S6K IC50:650nM
实施例13 5-((-4-((3-氟苯基)氨基甲酰基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰 胺(反式_外消旋物)
通过与3-氨基-4-((3-氟苯基)氨基甲酰基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=395,obsd.=395)。
p70S6K IC50:290nM
实施例14 5-(((4-(苯基氨基甲酰基)哌啶-4-基)甲基)氨基)喹唑啉-8-羧酰胺 (外消旋物)
通过与2-(三甲基硅烷基)乙基4-(氨基甲基)-4-(苯基氨基甲酰基)哌啶-1-羧酸酯(外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=404,obsd.=405)。
p70S6K IC50:>1000nM
实施例15 5-(3-氨基-3-(苯基氨基甲酰基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与(3-(苯基氨基甲酰基)吡咯烷-3-基)氨基甲酸叔丁酯(外消旋物)进行偶联反应,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=377,obsd.=377)。
p70S6K IC50:2300nM
实施例16 (S)-5-((1-(3-氟苯基)-2-(甲基氨基)乙基)氨基)喹啉-8-羧酰胺(手 性)
5-溴-喹啉-8-羧酸甲酯(600.00mg;2.25mmol;1.00eq.)、N-[(S)-2-氨基-2-(3-氟-苯基)-乙基]-N-甲基-4-硝基-苯磺酰胺(876.48mg;2.48mmol;1.10eq.)、磷酸三钾(957.26mg;4.51mmol;2.00eq.)、二环己基-(2',4',6'-三异丙基-联苯基-2-基)-膦(214.99mg;0.45mmol;0.20eq.)、醋酸二钾(50.62mg;0.23mmol;0.10eq.)和甲苯(5ml)组成的反应混合物置于微波试管中,在100℃搅拌过夜。粗产物经制备型HPLC(碱性条件)纯化,得到(S)-5-{1-(3-氟-苯基)-2-[甲基-(4-硝基-苯磺酰基)-氨基]-乙基氨基}-喹啉-8-羧酸甲酯(250mg)。LC-MS(M+H=339,obsd.=339)。
把上述甲酯(250.00mg;0.46mmol;1.00eq.)加入7.0M氨在甲醇(15.00ml)中的溶液中,50℃搅拌5天。反应混合物浓缩,经制备型HPLC纯化,得到(S)-5-{1-(3-氟-苯基)-2-[甲基-(4-硝基-苯磺酰基)-氨基]-乙基氨基}-喹啉-8-羧酰胺,将其溶解在乙腈(5ml)中,加入苯硫酚(204.58mg;1.86mmol;4.00eq.)和Cs2CO3(605.00mg;1.86mmol;4.00eq.)。反应混合物室温搅拌过夜。经过一般程序处理后,残留物经制备型HPLC纯化,得到实施例16(30mg,19%)。LC-MS(M+H=339,obsd=339)。
p70S6K IC50:>1000nM
实施例17 5-((-4-(喹啉-7-基)吡咯烷-3-基)氨基)喹啉-8-羧酰胺(反式_外消旋物)
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与3-氨基-4-(喹啉-7-基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例17。LC-MS(M+H=384,obsd=384)。
p70S6K IC50:190nM
实施例18 5-(3-苯基哌嗪-1-基)喹啉-8-羧酰胺(外消旋物)
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与2-苯基哌嗪-1-羧酸叔丁酯进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例18。LC-MS.(M+H=333,obsd=333)。
p70S6K IC50:670nM
实施例19 5-((3-苯基氮杂环丁烷-3-基)氨基)喹啉-8-羧酰胺
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与3-氨基-3-苯基氮杂环丁烷-1-羧酸叔丁酯(外消旋物)进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例19。LC-MS(M+H=319,obsd=319)。
p70S6K IC50:>1000nM
实施例20 5-(((3-(苯基氨基甲酰基)吡咯烷-3-基)甲基)氨基)喹啉-8-羧酰胺(外消旋物)
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与3-(氨基甲基)-3-(苯基氨基甲酰基)吡咯烷-1-羧酸叔丁酯(外消旋物)进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例20。LC-MS(M+H=390,obsd.=390)。
p70S6K IC50:>1000nM
实施例21 5-((-4-(3-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹啉-8-羧酰胺(外消旋物_反式)
5-溴-喹啉-8-腈(200.00mg;0.86mmol;1.00eq)、(3-氨基-4-(3-三氟甲氧基-苯基)-吡咯烷-1-羧酸叔丁酯(0.41ml;1.03mmol;1.20eq.)(反式_外消旋物)、2-甲基-丙-2-醇钠(181.43mg;1.89mmol;2.20eq.)和二环己基-(2',4',6'-三异丙基-联苯基-2-基)-膦(122.73mg;0.26mmol;0.30eq.)和甲苯(5ml)组成的反应混合物置于微波试管中,脱气10分钟。然后置于100℃微波20分钟。反应混合物浓缩,重溶于DMSO中,经制备型HPLC(碱性条件,70%-75%乙腈在水中的溶液)纯化,得到3-(8-氰基-喹啉-5-基氨基)-4-(3-三氟甲氧基-苯基)-吡咯烷-1-羧酸叔丁酯(反式_外消旋物)(150mg,35%)。
把上述甲酯(250.00mg;0.46mmol;1.00eq.)加入7.0M氨在甲醇(15.00ml)中的溶液中,50℃搅拌5天。反应混合物浓缩,经制备型HPLC纯化,得到(S)-5-{1-(3-氟-苯基)-2-[甲基-(4-硝基-苯磺酰基)-氨基]-乙基氨基}-喹啉-8-羧酰胺,将其溶解在乙腈(5ml)中,加入苯硫酚(204.58mg;1.86mmol;4.00eq.)和Cs2CO3(605.00mg;1.86mmol;4.00eq.)。反应混合物室温搅拌过夜。经过一般程序处理后,残留物经制备型HPLC纯化,得到实施例16(30mg,19%)。
3-(8-氰基-喹啉-5-基氨基)-4-(3-三氟甲氧基-苯基)-吡咯烷-1-羧酸叔丁酯(反式_外消旋物)(136.00mg;0.27mmol;1.00eq.)在浓硫酸(2.00ml;37.52mmol;137.53eq.)中的反应混合物在100℃加热1小时。反应溶液冷却,将其倒入碎冰中。加入固体氢氧化钠以调至PH=9。把油分离出来,再经制备型HPLC纯化,得到实施例21(15mg)。LC-MS(M+H=417,obsd=417)。
p70S6K IC50:22nM
实施例22 5-(((4S)-4-(3-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹啉-8-羧酰 胺(手性,实施例21的第一个对映异构体,不知道绝对构型)
通过手性色谱法从外消旋物实施例21分离出标题化合物。LC-MS(M+H=417,obsd=417)。
p70S6K IC50:31nM
实施例23 5-(((3S,4R)-4-(3-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹啉-8-羧 酰胺(手性,实施例21的第二个对映异构体,不知道绝对构型)
通过手性色谱法从外消旋物实施例21分离出标题化合物。LC-MS(M+H=417,obsd=417)。1HNMR:(DMSO)9.92(s,1H),9.76(s,1H),8.20-8.23(d,1H),7.98-8.00(d,1H),7.30-7.32(d,1H),7.25(s,1H),7.15(t,1H),6.80-6.82(d,1H),4.60-4.63(m,1H),3.80-3.90(m,2H),3.65(t,1H),3.30(t,1H),3.20-3.25(m,1H)。
p70S6K IC50:690nM
实施例24 5-((-4-(3-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹啉-8-羧酰胺(外消旋物_顺式)
合成实施例21得到的副产物被分离出来就是标题化合物。LC-MS.(M+H=417,obsd.=417)。
p70S6K IC50:23nM
实施例25 5-((4-(3-氟苯基)哌啶-3-基)氨基)喹啉-8-羧酰胺(外消旋物_反式)
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与3-氨基-4-(3-氟苯基)哌啶-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例25。LC-MS(M+H=365,obsd.=365)。
p70S6K IC50:520nM
实施例26 5-(((4R)-4-(3-氯-5-氟苯基)吡咯烷-3-基)氨基)喹啉-8-羧酰胺(外消旋物_反式)
依据实施例16的制备方法合成标题化合物,采用5-溴喹唑啉-8-羧酸甲酯与3-氨基-4-(3-氯-5-氟苯基)吡咯烷-1-羧酸叔丁酯(反式_外消旋物)进行偶联反应,用氨在甲醇中的溶液将甲酯转化为酰胺,再进行N-Boc脱保护,得到实施例26。LC-MS.(M+H=385,obsd=384/386)。
p70S6K IC50:350nM
实施例27 5-((4S)-4-(3-氟苯基)吡咯烷-3-羧酰氨基)喹啉-8-羧酰胺(绝对手性)
5-氨基-喹啉-8-腈(1000.00mg;4.29mmol;1.00eq.)在硫酸(5.00ml;93.80mmol;21.86eq.)中的反应混合物在100℃搅拌1小时。反应混合物冷却,将其倒入冰中,用2N氢氧化钠中和至PH=9。滤出沉淀物,用水洗涤,干燥,得到5-氨基喹啉-8-羧酰胺(800mg,得率74.3%)。
向(3R,4S)-4-(3-氟-苯基)-吡咯烷-1,3-二羧酸叔丁酯(125.00mg;0.40mmol;1.00eq.)在DCE(4.0ml)中的溶液加入双(2-氧代-1,3-噁唑烷-3-基)次磷酰氯(102.87mg;0.40mmol;1.00eq.)。室温搅拌15分钟后,加入DIEA(0.15ml;0.81mmol;2.00eq.)和5-氨基喹啉-8-羧酰胺(75.65mg;0.40mmol;1.00eq)。反应混合物60℃下搅拌过夜。粗产物经制备型PLC纯化后得到(4S)-3-((8-氨基甲酰基喹啉-5-基)氨基甲酰基)-4-(3-氟苯基)吡咯烷-1-羧酸叔丁酯,将该酯加入1ml4.0M HCl和1ml甲醇中,室温搅拌3小时。反应混合物浓缩,中和至Ph7,再经制备型HPLC纯化,得到实施例27。(M+H=479,obsd=479)。
p70S6K IC50:>1000nM
实施例28 5-((4S)-4-苯基吡咯烷-2-羧酰氨基)喹啉-8-羧酰胺(绝对手性)
依据实施例27的制备方法合成标题化合物,采用5-氨基喹啉-8-羧酰胺与(4S)-1-(叔丁氧基羰基)-4-苯基吡咯烷-2-羧酸进行偶联反应,再脱去保护基,得到实施例28。LC-MS.(M+H=361,obsd=361)。
p70S6K IC50:578nM
实施例29 5-(2-氨基-2-苯基乙酰氨基)喹啉-8-羧酰胺(外消旋物)
依据实施例27的制备方法合成标题化合物,采用5-氨基喹啉-8-羧酰胺与2-((叔丁氧基羰基)氨基)-2-苯基乙酸进行偶联反应,再脱去保护基,得到实施例29。LC-MS(M+H=321,obsd=321)。
p70S6K IC50:>1000nM
实施例30 5-((3S)-3-苯基氮杂环丁烷-2-羧酰氨基)喹啉-8-羧酰胺(绝对手性)
依据实施例27的制备方法合成标题化合物,采用5-氨基喹啉-8-羧酰胺与(3S)-1-(叔丁氧基羰基)-3-苯基氮杂环丁烷-2-羧酸进行偶联反应,再脱去Boc保护基,得到实施例30。LC-MS(M+H=347,obsd=347)。
p70S6K IC50:>1000nM
实施例31 5-(4-氟苄基氨基)-喹啉-8-羧酰胺
向5-氨基喹啉-8-羧酰胺(120mg,0.64mmol)在无水DMF(2mL)中的溶液加入4-氟苄基溴化物(242.34mg,1.28mmol)和碳酸钾(531.56mg,3.85mmol)。悬液在50℃加热过夜。混合物用甲醇(4mL)稀释,滤出固体。粗产物通过反相HPLC纯化,得到实施例31(90mg)。LC-MS(M+H=296,obsd=296)。
p70S6K IC50:875nM
实施例32 5-(2-氟苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=296,obsd=296)。
p70S6K IC50:>1000nM
实施例33 5-(3-氟苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=296,obsd=296)。
p70S6K IC50:369nM
实施例34 5-(3-氯苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=312,obsd=312)。
p70S6K IC50:140nM
实施例35 5-(3,4-二氟苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=314,obsd=314)。
p70S6K IC50:>1000nM
实施例36 5-(3,4,5-三氟苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=332,obsd.=332)。
p70S6K IC50:>1000nM
实施例37 5-(4-氟-3-三氟甲基苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=364,obsd.=364)。
p70S6K IC50:695nM
实施例38 5-(4-氯-3-三氟甲基苄基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=380,obsd.=380)。
p70S6K IC50:>1000nM
实施例39 5-((1-苯基-2(吡咯烷-1-基)乙基)氨基-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=361,obsd.=361)。
p70S6K IC50:>1000nM
实施例40 5-(苯基乙基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=292,obsd.=292)。
p70S6K IC50:>1000nM
实施例41 5-(苯基丙基氨基)-喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=306,obsd.=306)。
p70S6K IC50:>1000nM
实施例42 5-(苄基氨基)喹啉-8-羧酰胺
依据实施例31的制备方法合成标题化合物。LC-MS(M+H=278,obsd=278)。
p70S6K IC50:680nM
实施例43 5-[3-氨基-3-[(4-氟苯基)氨基甲酰基]吡咯烷-1-基]喹唑啉-8-羧酰 胺(外消旋物)
通过与3-氨基-N-(4-氟苯基)吡咯烷-3-羧酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=395,obsd.=395)。1HNMR(400MHz,DMSO)δ13.03(s,0H),9.76(d,J=13.4Hz,2H),9.24–9.17(m,1H),8.54(t,J=9.2Hz,1H),7.75(dd,J=9.0,5.0Hz,2H),7.55(d,J=4.1Hz,1H),7.17(dd,J=16.2,7.4Hz,2H),6.88(t,J=8.2Hz,1H),4.36–4.26(m,1H),4.11(dd,J=16.7,9.7Hz,1H),3.68(d,J=10.4Hz,1H),2.08(t,J=8.5Hz,1H),1.45–1.18(m,1H)。
p70S6K IC50:1200nM
实施例44 5-(3-氨基-3-((3,4-二氟苯基)氨基甲酰基)吡咯烷-1-基)喹唑啉-8- 羧酰胺(外消旋物)
通过与3-氨基-N-(3,4-二氟苯基)吡咯烷-3-羧酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=413,obsd.=413)。1H NMR(400MHz,DMSO)δ9.79–9.71(m,2H),9.21(s,1H),8.56(d,J=8.9Hz,1H),7.93(ddd,J=13.3,7.5,2.5Hz,1H),7.59–7.49(m,2H),7.41(dd,J=19.7,9.1Hz,1H),6.89(d,J=9.0Hz,1H),4.31(d,J=10.3Hz,1H),4.10(dd,J=16.5,9.7Hz,1H),3.78(t,J=8.0Hz,1H),3.68(d,J=10.3Hz,1H),2.08(t,J=8.5Hz,1H)。
p70S6K IC50:1300nM
实施例45 5-(3-氨基-3-((3-氟苯基)氨基甲酰基)吡咯烷-1-基)喹唑啉-8-羧酰 胺(外消旋物)
通过与3-氨基-N-(3-氟苯基)吡咯烷-3-羧酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=395,obsd.=395)。1HNMR(400MHz,DMSO)δ13.48(s,1H),9.76(d,J=13.6Hz,2H),9.21(d,J=6.6Hz,1H),8.55(t,J=9.0Hz,1H),7.74(d,J=11.4Hz,1H),7.54(dd,J=28.9,10.7Hz,2H),7.42–7.26(m,1H),7.19(d,J=8.8Hz,1H),6.96–6.76(m,2H),5.22(s,1H),4.31(dd,J=19.8,11.2Hz,2H),4.11(s,1H),3.93–3.73(m,2H),3.69(d,J=10.3Hz,1H)。
p70S6K IC50:2000nM
实施例46 5-(3-氨基-3-((4-氟-3-(三氟甲基)苯基)氨基甲酰基)吡咯烷-1-基) 喹唑啉-8-羧酰胺(外消旋物)
通过与3-氨基-N-(4-氟-3-(三氟甲基)-苯基)吡咯烷-3-羧酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=395,obsd.=395)。1H NMR(400MHz,DMSO)δ9.81–9.68(m,2H),9.21(d,J=7.7Hz,1H),8.56(d,J=8.9Hz,1H),8.27(dd,J=6.4,2.6Hz,1H),8.10–8.00(m,1H),7.60–7.46(m,2H),6.88(t,J=8.2Hz,1H),4.32(d,J=10.4Hz,1H),4.10(dd,J=16.7,9.7Hz,1H),3.79(t,J=8.0Hz,1H),3.69(d,J=10.1Hz,1H),2.11(d,J=5.1Hz,1H)。
p70S6K IC50:270nM
实施例47 5-(3-(2-苯基乙酰氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与2-苯基-N-(吡咯烷-3-基)乙酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=376,obsd=376)。1H NMR(500MHz,dmso)δ9.75(d,J=9.8Hz,2H),9.21(d,J=1.3Hz,1H),8.59–8.52(m,1H),8.43(d,J=6.3Hz,1H),7.57(s,1H),7.23(td,J=15.7,8.0Hz,5H),6.88(d,J=8.9Hz,1H),4.37(s,1H),4.03(dd,J=10.2,6.0Hz,1H),3.85(t,J=8.5Hz,1H),3.76(s,1H),3.59–3.51(m,1H),3.40(s,2H),2.21(dd,J=12.6,6.0Hz,1H),2.00(d,J=5.3Hz,1H)。
p70S6K IC50:7900nM
实施例48 5-(3-(3-(三氟甲基)苯甲酰氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与N-(吡咯烷-3-基)-3-(三氟甲基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=430,obsd=430)。1HNMR(500MHz,dmso)δ9.81(s,1H),9.74(s,1H),9.22(s,1H),8.90(d,J=6.0Hz,1H),8.56(d,J=8.9Hz,1H),8.22–8.13(m,2H),7.92(d,J=8.0Hz,1H),7.73(t,J=8.0Hz,1H),7.57(s,1H),6.91(d,J=8.9Hz,1H),4.66(d,J=5.4Hz,1H),4.17–4.08(m,1H),3.93(s,1H),3.87–3.74(m,2H),2.99(s,0H),2.54(s,2H),2.33(d,J=6.1Hz,1H),2.20(s,1H)。
p70S6K IC50:2200nM
实施例49 5-(3-(苄基(2-(二甲基氨基)乙基)氨基甲酰基)吡咯烷-1-基)喹唑啉- 8-羧酰胺(外消旋物)
通过与N-苄基-N-(2-(二甲基氨基)乙基)吡咯烷-3-羧酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=447,obsd=447)。1H NMR(400MHz,DMSO)δ9.74(s,2H),9.21(d,J=4.5Hz,1H),8.54(t,J=9.1Hz,1H),7.55(s,1H),7.41–7.20(m,5H),6.88(dd,J=23.8,8.7Hz,1H),4.74(s,1H),4.65(d,J=15.0Hz,1H),4.55(d,J=14.6Hz,1H),3.91(ddd,J=23.2,16.7,8.5Hz,3H),3.73(s,1H),3.57(d,J=44.4Hz,2H),3.38(dd,J=14.9,7.8Hz,2H),3.00(s,1H),2.54(d,J=5.9Hz,1H),2.43–2.28(m,3H),2.12(d,J=14.3Hz,5H)。
p70S6K IC50:1600nM
实施例50 5-(3-(3,4-二氟苯甲酰氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与3,4-二氟-N-(吡咯烷-3-基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=398,obsd=398)。1H NMR(500MHz,dmso)δ9.81(s,1H),9.74(s,1H),9.22(s,1H),8.71(d,J=6.2Hz,1H),8.56(d,J=8.7Hz,1H),7.97–7.88(m,1H),7.76(s,1H),7.56(dt,J=16.9,8.6Hz,2H),6.90(d,J=8.9Hz,1H),4.64–4.58(m,1H),4.10(dd,J=10.4,6.1Hz,1H),3.97–3.88(m,1H),3.82(s,1H),3.74(dd,J=10.7,4.3Hz,1H),2.30(dd,J=12.9,5.9Hz,1H),2.17(d,J=5.2Hz,1H)。
p70S6K IC50:380nM
实施例51 5-(3-(2-(4-氟苯基)乙酰氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与2-(4-氟苯基)-N-(吡咯烷-3-基)-乙酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=394,obsd=394)。1HNMR(400MHz,DMSO)δ9.76(s,2H),9.21(s,1H),8.55(d,J=8.5Hz,1H),8.44(d,J=6.0Hz,1H),7.59(s,1H),7.25(s,2H),7.08(t,J=8.0Hz,2H),6.88(d,J=9.0Hz,1H),4.36(s,1H),4.04(d,J=6.6Hz,1H),3.85(s,1H),3.77(s,1H),3.54(d,J=10.1Hz,1H),3.38(d,J=14.2Hz,2H),2.20(s,1H),1.99(s,1H)。
p70S6K IC50:5400nM
实施例52 5-(3-((3,4-二氯苄基)氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与N-(3,4-二氯苄基)吡咯烷-3-胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=417,obsd=417)。1H NMR(500MHz,dmso)δ9.73(s,2H),9.18(s,1H),8.52(d,J=8.9Hz,1H),7.59(d,J=1.8Hz,1H),7.55–7.47(m,2H),7.34–7.28(m,1H),6.82(d,J=9.0Hz,1H),3.91(dd,J=10.4,5.5Hz,1H),3.88–3.81(m,1H),3.74(s,2H),3.68(s,1H),3.54(dd,J=10.3,3.9Hz,1H),3.38(s,1H),2.63(s,1H),2.13–2.04(m,1H),1.94(d,J=5.3Hz,1H)。
p70S6K IC50:490nM
实施例53 5-(3-((3,4-二氯苄基)(甲基)氨基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与N-(3,4-二氯苄基)-N-甲基吡咯烷-3-胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=431,obsd=431)。1HNMR(400MHz,DMSO)δ9.78(d,J=17.6Hz,2H),9.21(s,1H),8.54(d,J=8.7Hz,1H),7.63–7.50(m,3H),7.34(d,J=8.1Hz,1H),6.90(d,J=8.9Hz,1H),3.94–3.73(m,4H),3.61(s,2H),3.20(s,2H),2.27(s,2H),2.18(s,3H),2.06–1.93(m,2H),0.08(s,1H)。
p70S6K IC50:570nM
实施例54 5-(3-((3,4-二氟苯甲酰氨基)甲基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与3,4-二氟-N-(吡咯烷-3-基甲基)-苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=412,obsd=412)。1H NMR(400MHz,DMSO)δ9.81(s,1H),9.75(d,J=4.0Hz,1H),9.20(s,1H),8.72(t,J=5.6Hz,1H),8.53(d,J=8.9Hz,1H),7.89(ddd,J=11.5,7.8,2.0Hz,1H),7.74(dd,J=5.1,3.3Hz,1H),7.62–7.50(m,2H),6.85(d,J=9.0Hz,1H),3.92–3.74(m,3H),3.65(dd,J=10.2,7.0Hz,1H),3.41(dtd,J=19.7,13.3,6.1Hz,2H),2.63(dt,J=13.7,6.8Hz,1H),2.16(td,J=12.0,5.9Hz,1H),1.85(dq,J=15.2,7.5Hz,1H)。
p70S6K IC50:233nM
实施例55 5-(3-((2-氟-4-(三氟甲基)苯甲酰氨基)甲基)吡咯烷-1-基)喹唑啉- 8-羧酰胺(外消旋物)
通过与2-氟-N-(吡咯烷-3-基甲基)-4-(三氟甲基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=462,obsd=462)。1H NMR(400MHz,DMSO)δ10.87(s,1H),9.80(s,1H),9.75(d,J=3.9Hz,1H),9.19(s,1H),8.53(d,J=8.9Hz,1H),7.89(d,J=8.1Hz,1H),7.52(d,J=3.8Hz,1H),6.90–6.80(m,2H),6.72(d,J=8.0Hz,1H),3.87–3.77(m,3H),3.61(dd,J=10.1,7.3Hz,1H),3.45(s,2H),2.71–2.57(m,1H),2.14(dt,J=19.7,7.0Hz,1H),1.93–1.79(m,1H)。
p70S6K IC50:290nM
实施例56 5-(3-(氨基甲基)哌啶-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与3-N-boc-氨基甲基哌啶(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=287,obsd.=286.2/287.2)。
P70S6K IC50:56000nM AKT IC50:>100000nM
实施例57 5-((1-(间甲苯基)哌啶-4-基)氨基)喹唑啉-8-羧酰胺
通过5-溴-喹唑啉-8-腈与1-(间甲苯基)哌啶-4-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=363,obsd.=362.2/363.3)。
P70S6K IC50:22000nM AKT IC50:>100000nM
实施例58 5-((1-甲基吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与1-甲基吡咯烷-3-胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=273,obsd.=272.1/273.1)。
P70S6K IC50:20000nM AKT IC50:>100000nM
实施例59 5-(3-((甲基氨基)甲基)哌啶-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与(哌啶-3-基甲基)氨基甲酸叔丁基甲酯(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=300,obsd.=300.1/301.1)。
P70S6K IC50:5900nM AKT IC50:18000nM
实施例60 (R)-5-((吡咯烷-3-基甲基)氨基)喹唑啉-8-羧酰胺(手性)
通过5-溴-喹唑啉-8-腈与(S)-3-(氨基甲基)吡咯烷-1-羧酸叔丁酯进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=273,obsd.=272.1/273.1)。
P70S6K IC50:4800nM AKT IC50:>100000nM
实施例61 (S)-5-((吡咯烷-3-基甲基)氨基)喹唑啉-8-羧酰胺(手性)
通过5-溴-喹唑啉-8-腈与(R)-3-(氨基甲基)吡咯烷-1-羧酸叔丁酯进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=273,obsd.=272.1/273.1)。
P70S6K IC50:1700nM AKT IC50:>100000nM
实施例62 5-((吡啶-3-基甲基)氨基)喹唑啉-8-羧酰胺
通过5-溴-喹唑啉-8-腈与吡啶-3-基甲胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=279,obsd.=280.1/281.1)。
P70S6K IC50:1600nM AKT IC50:70000nM
实施例63 5-((3-氯苄基)氨基)喹唑啉-8-羧酰胺
通过5-溴-喹唑啉-8-腈与(3-氯苯基)甲胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=313,obsd.=313.1/314.1)。
P70S6K IC50:59.2nM AKT IC50:12000nM
实施例64 5-(3-苯乙基吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与3-苯乙基吡咯烷(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=347,obsd.=347.2/348.2)。
P70S6K IC50:240nM AKT IC50:3100nM
实施例65 5-(3-(苄基氧基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与3-(苄基氧基)吡咯烷(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=349,obsd.=349.1/350.1)。
P70S6K IC50:710nM AKT IC50:>100000nM
实施例66 5-(3-羟基-3-苯基吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与3-苯基吡咯烷-3-醇(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=335,obsd.=335.1/336.1)。
P70S6K IC50:1800nM AKT IC50:>100000nM
实施例67 5-((3S,4R)-3-(羟基甲基)-4-(间甲苯基)吡咯烷-1-基)喹唑啉-8-羧 酰胺(手性)
通过5-溴-喹唑啉-8-腈与((3S,4R)-4-(间甲苯基)吡咯烷-3-基)甲醇进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=363,obsd.=363.2/364.1)。
P70S6K IC50:190nM AKT IC50:8200nM
实施例68 5-((2-(3-氯苯基)-2-(二甲基氨基)乙基)氨基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与1-(3-氯苯基)-N1,N1-二甲基乙烷-1,2-二胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=370,obsd.=370.1/371.1)。
P70S6K IC50:2600nM AKT IC50:>100000nM
实施例69 5-((2-苯基-2-(哌嗪-1-基)乙基)氨基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与4-(2-氨基-1-苯基乙基)哌嗪-1-羧酸叔丁酯(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=363,obsd.=363.2/364.1)。
P70S6K IC50:170nM AKT IC50:10000nM
实施例70 5-((3-(4-氟苯基)哌啶-4-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与4-氨基-3-(4-氟苯基)哌啶-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd.=366.1/367.2)。
P70S6K IC50:550nM AKT IC50:2500nM
实施例71 5-((4-(3-(三氟甲基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(3-(三氟甲基)苯基)吡咯烷-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=402,obsd.=402.2)。
P70S6K IC50:21nM AKT IC50:4500nM
实施例72 5-((4-(3-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(3-(三氟甲氧基)苯基)吡咯烷-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=418,obsd.=418.2/418.9)。
P70S6K IC50:100nM AKT IC50:>100000nM
实施例73 5-((4-(间甲苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(间甲苯基)哌啶-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=362,obsd.=362.2/363.2)。
P70S6K IC50:390nM AKT IC50:9000nM
实施例74 5-((4-(3-(三氟甲基)苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(3-(三氟甲基)苯基)哌啶-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=416,obsd.=416.2/417.2)。
P70S6K IC50:140nM AKT IC50:2100nM
实施例75 5-((4-(4-氯-3-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(4-氯-3-氟苯基)哌啶-1-羧酸叔丁酯非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=400.8,obsd.=400.2)。
P70S6K IC50:8.1nM AKT IC50:130nM
实施例76 5-((4-(3-氯-4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(3-氯-4-氟苯基)哌啶-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=400.8,obsd.=400.1/401.1)。
P70S6K IC50:33nM AKT IC50:570nM
实施例77 5-(((3R,4R)-4-(3-氯-4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(手性,实施例76的对映异构体之一,不知道绝对构型)
通过手性SFC法从实施例76的非对映异构体的混合物分离出标题化合物。LC-MS(M+H=400.8,obsd.=400.1/401.1)。1HNMR(MeOH-d4)δ1.16(m,1H),1.31(m,1H),1.78(m,1H),2.34(m,1H),2.89(m,1H),3.20-3.32(m,3H),6.29(m,1H),6.97(m,1H),7.25(m,1H),7.39(m,1H),8.33(m,1H),9.21(s,1H),9.93(s,1H)。
P70S6K IC50:50nM AKT IC50:850nM
实施例78 5-(((3S,4S)-4-(3-氯-4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(手性,实施例76的对映异构体之一,不知道绝对构型)
通过手性SFC法从实施例76的非对映异构体的混合物分离出标题化合物。LC-MS(M+H=400.8,obsd.=400.2)。
P70S6K IC50:350nM AKT IC50:5700nM
实施例79 5-((4-(4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(非对映异构体的外消旋混合物)
通过5-溴-喹唑啉-8-腈与3-氨基-4-(4-氟苯基)哌啶-1-羧酸叔丁酯(非对映异构体的外消旋混合物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd.=366.1/367.1)。
P70S6K IC50:290nM AKT IC50:2000nM
实施例80 5-(((3R,4R)-4-(4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(手性,实施例79的对映异构体之一,不知道绝对构型)
通过手性SFC法从实施例79的非对映异构体的混合物分离出标题化合物。LC-MS(M+H=366,obsd.=366.2)。
P70S6K IC50:290nM AKT IC50:2200nM
实施例81 5-(((3S,4S)-4-(4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺(手性,实施例79的对映异构体之一,不知道绝对构型)
通过手性SFC法从实施例79的非对映异构体的混合物分离出标题化合物。LC-MS(M+H=366,obsd.=366.1)。
P70S6K IC50:52nM AKT IC50:900nM
实施例82 5-(3-氨基-4-苯基哌啶-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与4-苯基-哌啶-3-基胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=347,obsd=348)。
P70S6K IC50:120nM
实施例83 5-(3-氨基-4-(4-(三氟甲基)苯基)哌啶-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过5-溴-喹唑啉-8-腈与4-(4-三氟甲基-苯基)-哌啶-3-基胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=415,obsd=416)。
P70S6K IC50:350nM
实施例84 (S)-5-(3-氨基-3-(苯基氨基甲酰基)吡咯烷-1-基)喹唑啉-8-羧酰胺(纯对映异构体,不知道绝对构型)
通过手性HPLC色谱法从实施例15分离出标题化合物。LC-MS(M+H=376,obsd=377)。
P70S6K IC50:2150nM
实施例85 (R)-5-(3-氨基-3-(苯基氨基甲酰基)吡咯烷-1-基)喹唑啉-8-羧酰胺(纯对映异构体,不知道绝对结构)
通过手性HPLC色谱法从实施例15分离出标题化合物。LC-MS(M+H=376,obsd=377)。
P70S6K IC50:11500nM
实施例86 5-[(3S,4R)-3-氨基-4-(4-氟-苯基)-哌啶-1-基]-喹唑啉-8-羧酸酰胺(外消旋物_顺式)
通过5-溴-喹唑啉-8-腈与顺-4-(4-氟苯基)哌啶-3-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd=366)。
P70S6K IC50:250nM
实施例87 5-[(3R,4R)-3-氨基-4-(4-氟-苯基)-哌啶-1-基]-喹唑啉-8-羧酸酰胺(外消旋物_反式)
通过5-溴-喹唑啉-8-腈与反-4-(4-氟苯基)哌啶-3-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd=366)。
P70S6K IC50:7100nM
实施例88 5-[(3S,4R)-3-氨基-4-(3-氟-苯基)-哌啶-1-基]-喹唑啉-8-羧酸酰胺(外消旋物_顺式)
通过5-溴-喹唑啉-8-腈与顺-4-(3-氟苯基)哌啶-3-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd=366)。
P70S6K IC50:17100nM
实施例89 5-[(3R,4R)-3-氨基-4-(3-氟-苯基)-哌啶-1-基]-喹唑啉-8-羧酸酰胺(外消旋物_反式)
通过5-溴-喹唑啉-8-腈与反-4-(3-氟苯基)哌啶-3-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=366,obsd=366)。
P70S6K IC50:2400nM
实施例90 5-[4-(4-三氟甲基-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈与1-(4-三氟甲基-苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=402,obsd=402)。
P70S6K IC50:24000nM AKT IC50:>100000nM
实施例91 5-[4-苯基-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈与1-苯基哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=334,obsd=334)。
P70S6K IC50:3000nM AKT IC50:15000nM
实施例92 5-[4-(3,4-二氟-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈和1-(3,4-二氟-苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=370,obsd=370)。
P70S6K IC50:1000nM AKT IC50:>100000nM
实施例93 5-[4-(4-氯-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈和1-(4-氯苯基)哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=368,obsd=368)。
P70S6K IC50:1000nM
实施例94 5-[4-(3-氯-4-氟苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈和1-(3-氯-4-氟-苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=386,obsd=386)。
P70S6K IC50:12000nM AKT IC50:>100000nM
实施例95 5-[4-(3-氟-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈和1-(3-氟-苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=352,obsd=352)。
P70S6K IC50:770nM AKT IC50:6400nM
实施例96 5-[4-(3-氯-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过5-溴-喹唑啉-8-腈和1-(3-氯l-苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=368,obsd=368)。
P70S6K IC50:10000nM AKT IC50:>100000nM
实施例97 5-(苄基氨基)喹唑啉-8-羧酰胺
通过与苄基胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=261,obsd=261)。1H NMR(400MHz,DMSO)δ9.96(s,1H),9.30(s,1H),8.83(t,J=5.6Hz,1H),8.11(d,J=8.6Hz,1H),7.42(d,J=7.7Hz,2H),7.35(t,J=7.3Hz,2H),7.27(t,J=6.9Hz,1H),6.62(d,J=8.7Hz,1H),4.64(d,J=5.8Hz,2H)。
p70S6K IC50:=690nM AKT IC50:=57000nM
实施例98 5-(苯乙基氨基)喹唑啉-8-羧酰胺
通过与2-苯乙基胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=293,obsd=293)。1H NMR(500MHz,dmso)δ9.84(s,1H),9.69(d,J=3.9Hz,1H),9.26(s,1H),8.56(d,J=8.7Hz,1H),7.86(t,J=5.3Hz,1H),7.52(d,J=3.9Hz,1H),7.39–7.27(m,4H),7.26–7.19(m,1H),6.85(d,J=8.8Hz,1H),3.62–3.52(m,2H),3.04–2.97(m,2H)。
p70S6K IC50:=89nM;AKT IC50:=5600nM
实施例99 5-[2-(3-氟苯基)乙基氨基]喹唑啉-8-羧酰胺
通过与2-(3-氟苯基)乙胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=311,obsd=311)。1H NMR(500MHz,dmso)δ9.83(s,1H),9.69(d,J=3.9Hz,1H),9.26(s,1H),8.56(d,J=8.7Hz,1H),7.84(t,J=5.5Hz,1H),7.52(d,J=3.9Hz,1H),7.38–7.30(m,1H),7.24–7.18(m,1H),7.16(d,J=7.6Hz,1H),7.04(td,J=8.6,2.5Hz,1H),6.87(d,J=8.8Hz,1H),3.59(dd,J=13.9,6.4Hz,2H),3.06–2.98(m,2H)。
p70S6K IC50:=120nM AKT IC50:=2400nM
实施例100 5-[2-(4-氟苯基)乙基氨基]喹唑啉-8-羧酰胺
通过与2-(4-氟苯基)乙胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=311,obsd=311)。1H NMR(500MHz,dmso)δ9.83(s,1H),9.69(d,J=3.9Hz,1H),9.26(s,1H),8.55(d,J=8.7Hz,1H),7.84(t,J=5.4Hz,1H),7.52(d,J=3.8Hz,1H),7.39–7.31(m,2H),7.16–7.07(m,2H),6.85(d,J=8.8Hz,1H),3.55(dd,J=14.0,6.4Hz,2H),3.03–2.95(m,2H)。
p70S6K IC50:=290nM AKT IC50:=4800nM
实施例101 5-[2-(3,4-二氟苯基)乙基氨基]喹唑啉-8-羧酰胺
通过与2-(3,4-二氟苯基)乙胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=329,obsd=329)。1H NMR(500MHz,dmso)δ9.82(s,1H),9.69(d,J=3.9Hz,1H),9.26(s,1H),8.56(d,J=8.7Hz,1H),7.81(t,J=5.3Hz,1H),7.53(d,J=3.7Hz,1H),7.45(ddd,J=12.0,7.9,2.0Hz,1H),7.35(dt,J=10.9,8.5Hz,1H),7.15(s,1H),6.87(d,J=8.8Hz,1H),3.57(dd,J=13.7,6.4Hz,2H),2.99(t,J=7.3Hz,2H)。
p70S6K IC50:=360nM AKT IC50:=41000nM
实施例102 5-(4-苯基丁基氨基)喹唑啉-8-羧酰胺
通过与4-苯基丁烷-1-胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=321,obsd=321)。1H NMR(500MHz,dmso)δ9.86(s,1H),9.68(d,J=3.9Hz,1H),9.24(s,1H),8.53(d,J=8.7Hz,1H),7.74(t,J=5.2Hz,1H),7.50(d,J=3.9Hz,1H),7.27(t,J=7.6Hz,2H),7.22(d,J=7.0Hz,2H),7.17(t,J=7.2Hz,1H),6.75(d,J=8.8Hz,1H),3.34(dd,J=12.1,6.8Hz,2H),2.66(t,J=7.1Hz,2H),1.79–1.62(m,4H)。
p70S6K IC50:=87nM AKT IC50:>100000nM
实施例103 5-[甲基(苯乙基)氨基]喹唑啉-8-羧酰胺
通过与N-甲基-2-苯基乙胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=307,obsd=307)。1H NMR(500MHz,dmso)δ9.71(d,J=2.5Hz,1H),9.48(s,1H),9.29(s,1H),8.59(d,J=8.4Hz,1H),7.76(d,J=2.4Hz,1H),7.32–7.19(m,5H),7.18(M,1H),3.60(t,2H),3.13(s,3H),2.99(t,2H)。
p70S6K IC50:=220nM AKT IC50:=14000nM
实施例104 5-[2-(3,4-二氯苯基)乙基氨基]喹唑啉-8-羧酰胺
通过与2-(3,4-二氯苯基)乙胺进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=362,obsd=362)。1H NMR(500MHz,cd3od)δ9.65(s,1H),9.22(s,1H),8.69(d,J=8.8Hz,1H),7.48(d,J=1.9Hz,1H),7.44(d,J=8.2Hz,1H),7.22(dd,J=8.3,2.0Hz,1H),6.89(d,J=8.8Hz,1H),3.71–3.64(m,2H),3.05(t,J=7.3Hz,2H)。
p70S6K IC50:=98nM AKT IC50:>100000nM
实施例105 5-[苯乙基-[(3R)-3-哌啶基]氨基]喹唑啉-8-羧酰胺(手性)
通过与(R)-3-(苯乙基氨基)哌啶-1-羧酸叔丁酯(流程7)进行偶联反应,再水解腈中间体并脱保护,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=376,obsd=376)。1H NMR(500MHz,dmso)δ10.34(s,1H),8.39(s,1H),7.95(d,J=8.4Hz,1H),7.41(s,1H),7.32–7.06(m,5H),6.88(d,J=8.7Hz,1H),5.56(s,1H),3.57–3.47(m,1H),3.26–3.10(m,2H),2.93–2.74(m,3H),2.68–2.60(m,1H),2.42–2.33(m,1H),2.07–1.99(m,1H),1.93–1.75(m,2H),1.74–1.56(m,2H),1.27–1.19(m,1H)。
p70S6K IC50:=11000nM AKT IC50:>100000nM
实施例106 5-(3-((2,5-二氟苯甲酰氨基)甲基)吡咯烷-1-基)喹唑啉-8-羧酰胺(外消旋物)
通过与2,5-二氟-N-(吡咯烷-3-基甲基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=412,obsd=412)。1HNMR(400MHz,DMSO)δ9.81(s,1H),9.75(d,J=4.2Hz,1H),9.21(s,1H),8.62(s,1H),8.54(d,J=8.8Hz,1H),7.53(s,1H),7.49–7.32(m,4H),6.85(d,J=8.9Hz,1H),3.90–3.82(m,1H),3.82–3.75(m,2H),3.69–3.61(m,1H),3.41(ddd,J=34.0,13.6,7.3Hz,3H),2.67–2.58(m,1H),2.16(dd,J=12.1,6.2Hz,1H),1.90–1.79(m,1H)。
p70S6K IC50:510nM
实施例107 5-[3-氨基-4-(3-三氟甲基-苯基)-哌啶-1-基]-喹唑啉-8-羧酸酰胺(外消旋物)
通过与5-溴-喹唑啉-8-腈和(4-(3-(三氟甲基)苯基)哌啶-3-基)氨基甲酸叔丁酯进行偶联反应,再水解腈中间体并脱保护,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=416,obsd=416)。
P70S6K IC50:380nM AKt IC50:8100nM
实施例108 5-[4-(4-氟苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(4-氟苯基)哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=352,obsd=352)。
P70S6K IC50:2300nM AKt IC50:>100000nM
实施例109 5-[4-(3-三氟甲基苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(3-三氟甲基氟苯基)哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=402,obsd=402)。
P70S6K IC50:11000nM AKt IC50:23000nM
实施例110 5-[4-(3,4-二氯苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(3,4-二氯苯基)-哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=403,obsd=403)。
P70S6K IC50:>100000nM AKt IC50:>100000nM
实施例111 5-[4-(5-氯-2-甲基苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(5-氯-2-甲基苯基)哌嗪进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=382,obsd=382)。
P70S6K IC50:>100000nM AKt IC50:>100000nM
实施例112 5-{3-[(2,4-二氟-苯甲酰基氨基)-甲基]-吡咯烷-1-基}-喹唑啉-8- 羧酸酰胺(外消旋物)
通过与2,4-二氟-N-(吡咯烷-3-基甲基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=412,obsd=412)。
p70S6K IC50:260nM
实施例113 5-{3-[(3-三氟甲基-苯甲酰基氨基)-甲基]-吡咯烷-1-基}-喹唑啉- 8-羧酸酰胺(外消旋物)
通过与N-(吡咯烷-3-基甲基)-3-(三氟甲基)苯甲酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=444,obsd=444)。
p70S6K IC50:nd nM
实施例114 5-{(R)-3-[(3,4-二氟-苯甲酰基氨基)-甲基]-吡咯烷-1-基}-喹唑 啉-8-羧酸酰胺(纯对映异构体,不知道绝对结构)
通过手性HPLC色谱法从实施例54分离出标题化合物。LC-MS(M+H=412,obsd=412)。1H NMR(400MHz,DMSO)δ9.77(d,J=26.9Hz,2H),9.20(s,1H),8.71(s,1H),8.53(d,J=7.2Hz,1H),7.95–7.83(m,1H),7.70(d,J=13.6Hz,4H),7.61–7.45(m,2H),6.84(d,J=8.5Hz,1H),4.30–3.97(m,4H),3.84(dd,J=23.0,14.6Hz,3H),3.68–3.59(m,1H),3.44(s,1H),2.63(dd,J=17.2,8.6Hz,1H),2.14(s,1H),1.82(s,2H),1.63(s,3H),1.26(d,J=18.5Hz,19H),0.95–0.66(m,15H)。
p70S6K IC50:470nM
实施例115 5-{(S)-3-[(3,4-二氟-苯甲酰基氨基)-甲基]-吡咯烷-1-基}-喹唑 啉-8-羧酸酰胺(纯对映异构体,不知道绝对结构)
通过手性HPLC色谱法从实施例54分离出标题化合物。LC-MS(M+H=412,obsd=412)。1H NMR(400MHz,DMSO)δ9.82(s,1H),9.75(s,1H),9.21(s,1H),8.79(s,1H),8.54(d,J=8.8Hz,2H),7.91(s,1H),7.76(s,1H),7.56(d,J=10.0Hz,2H),6.86(d,J=9.2Hz,1H),4.37(s,4H),3.83(d,J=28.4Hz,3H),3.64(s,2H),3.45(d,J=6.2Hz,5H),3.15(d,J=29.4Hz,2H),2.94(s,1H),2.15(s,2H),1.88(s,1H),1.59(s,2H),1.25(s,4H),1.05(dd,J=18.1,12.1Hz,9H),0.84(s,2H)。
p70S6K IC50:450nM
实施例116 5-[(S)-3-氨基-3-(4-氟-3-三氟甲基-苯基氨基甲酰基)-吡咯烷-1- 基]-喹唑啉-8-羧酸酰胺(纯对映异构体,不知道绝对结构)
通过手性HPLC色谱法从实施例46分离出标题化合物。LC-MS(M+H=463,obsd=463)。1H NMR(400MHz,DMSO)δ9.77(d,J=12.8Hz,2H),9.22(s,1H),8.56(d,J=9.0Hz,1H),8.28(s,1H),8.06(s,1H),7.61–7.46(m,2H),6.90(d,J=8.7Hz,1H),4.33(d,J=10.7Hz,1H),4.11(s,2H),3.79(s,1H),3.70(d,J=9.1Hz,1H),2.10(s,2H)。
p70S6K IC50:520nM
实施例117 5-[(R)-3-氨基-3-(4-氟-3-三氟甲基-苯基氨基甲酰基)-吡咯烷-1- 基]-喹唑啉-8-羧酸酰胺(纯对映异构体,不知道绝对结构)
通过手性HPLC色谱法从实施例46分离出标题化合物。LC-MS(M+H=463,obsd=463)。1H NMR(400MHz,DMSO)δ9.76(d,J=12.2Hz,2H),9.22(s,1H),8.56(d,J=7.4Hz,1H),8.27(s,1H),8.05(s,1H),7.62–7.44(m,2H),6.89(d,J=8.8Hz,1H),4.32(d,J=9.8Hz,1H),4.10(d,J=8.5Hz,1H),3.79(s,1H),3.69(d,J=10.3Hz,1H),2.10(s,2H)。
p70S6K IC50:380nM
实施例118 5-{3-[(2,4-二氟-苯甲酰基氨基)-甲基]-吡咯烷-1-基}-喹唑啉-8- 羧酸酰胺(外消旋物)
通过与2-苯基-N-(吡咯烷-3-基甲基)乙酰胺(外消旋物)进行偶联反应,再水解腈中间体,依据实施例1的制备方法合成标题化合物。LC-MS(M+H=390,obsd.=390)。1H NMR(400MHz,DMSO)δ9.81–9.70(m,2H),9.21(s,1H),8.53(d,J=8.9Hz,1H),8.22(t,J=5.5Hz,1H),7.54(d,J=3.7Hz,1H),7.33–7.24(m,4H),7.24–7.16(m,1H),6.81(d,J=8.9Hz,1H),3.76(dd,J=14.9,8.1Hz,3H),3.54(dd,J=10.2,7.2Hz,1H),3.43(s,2H),3.21(dtd,J=19.7,13.3,6.2Hz,2H),2.08(dd,J=11.8,5.9Hz,1H),1.83–1.67(m,1H)。
p70S6K IC50:260nM
实施例119 5-[4-(2-氯-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(2-氯-苯基)-哌嗪进行偶联反应,再进行水解,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=368,obsd=368)。
P70S6K IC50:400nM
实施例120 5-[4-(2-甲基-苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(2-甲基-苯基)-哌嗪进行偶联反应,再进行水解,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=348,obsd=348)。
P70S6K IC50:980nM
实施例121 5-[4-(2-氟苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(2-氟苯基)-哌嗪进行偶联反应,再进行水解,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=352,obsd=352)。
P70S6K IC50:12000nM
实施例122 5-[4-(2-甲氧基苯基)-哌嗪-1-基]-喹唑啉-8-羧酸酰胺
通过与5-溴-喹唑啉-8-腈和1-(2-甲氧基苯基)-哌嗪进行偶联反应,再进行水解,依据实施例1的制备方法合成标题化合物。LC-MS.(M+H=364,obsd=364)。
P70S6K IC50:11000nM
生物活性
P70S6K酶试验
将P70S6K抑制剂化合物稀释,并铺于96孔板中。将包含以下组分的反应混合液加入该化合物板中以开始酶反应;将P70S6K(3nM,T412E突变体,Millipore)与24μMATP在试验缓冲液中混合,所述缓冲液包含100mM Hepes(pH7.5)、5mM MgCl2、1mMDTT、0.015%Brij和1μM底物肽FITC-AHA-AKRRRLSSLRA-OH(源自S6核糖体蛋白质序列,FITC=异硫氰酸荧光素,AHA=6-氨基己酸)。将该反应物在25℃孵育90分钟,之后加入10mM EDTA以停止该反应。在Caliper Life Sciences Lab Chip3000分析底物和产物(磷酸化的)肽的比例,压力为-1.4psi,下游电压和下游电压分别为-3000和-700。在获得色谱图上,解析出产物峰在底物峰之前。
AKT酶试验
采用TTP Mosquito液体处理仪器,在384孔板的每个孔内放置125nl在100%DMSO中适当浓度的抑制剂(用于绘制剂量反应曲线)。向该反应加入各组分至终浓度为12.5μl:
0.1ng/μl His-AKT(全长),(Invitrogen,Part#P2999,Lot#641228C)
160uM ATP(Fluka,02055)
1mM DTT(Sigma,D0632)
1mM MgCl2(Sigma,M1028)
1μM底物肽(序列FITC-AHA-GRPRTSSFAEG-NH2),由Tufts Peptide Synthesisservice合成
100mM HEPES pH7.5(Calbiochem,391338)
0.015%Brij-35(Sigma,B4184)
反应在25℃培育90分钟,然后加入70μl终止缓冲液(100mM HEPES pH7.5,0.015%Brij-35,10mM EDTA(Sigma,E7889))终止反应。
用Caliper LC3000读取孔板,读取格式为芯片外迁移率试验格式(Off-Chipmobility shift assay format),采用具有12个吸入针的芯片,参数如下:筛选压力–2.3psi,上游电压–500,下游电压–3000。这些条件使得未磷酸化底物和磷酸化产物以不同峰分辨出来,因此可以直接测量底物转化为产物的百分比。将转化百分比与抑制剂浓度绘制成曲线,得到S形剂量应答曲线,基于该S形曲线可以计算IC50值。
Claims (24)
1.如以下通式(I)所示的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,
其中:
X是N;
Y是N-R5;
R1是L1-R6、或者L1-R6-L2-R7;
R2是H或Hal;
R3是H;
R5是H、LA或者是具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被-NH-所替代,或者
R5、R1一起形成具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被O原子和/或–NH-、-NA-、-N(L1-R6)-、-CHA-、-CA2-、CH(L1-R6)-或者-CO-基团所替代,并且所述单环烷基可以被NH2取代;
L1、L2独立地是单键,或者是具有1、2、3、4或5个C原子的无支链的或有支链的烷基,所述烷基可以未被取代或被Hal单取代或二取代,其中1个或2个CH2基团可以被-CO-、-NH-、-N(LA)-、-CONH-、-N(LA)COO-或者-NHCO-基团所替代;
R6是Ar或者是具有3、4、5、6或7个环原子的单环烷基,其中1个或2个CH2基团可以被–NH-或-NA-基团所替代;
R7是苯基,所述苯基可以未被取代或者独立地被Hal、C(Hal)3、CH3、CH3O、或者C(Hal)3O单取代、二取代或三取代;
Ar是具有0、1、2、3或4个N、O和/或S原子和5、6、8、9或10个骨架原子的单环或二环的芳族碳环或杂环,所述碳环或杂环可以未被取代或相互独立地被Hal、A、OA、OH、NH2、或者NHA单取代、二取代或三取代;
A是具有1、2、3、4、5或6个C原子的无支链的或有支链的直链烷基或者环状烷基,其中1个或2个CH2基团可以被O原子和/或–NH-、-NHCO或者–CONH基团所替代,其中1-3个H原子可以被Hal所替代,并且其中1个或2个CH3基团可以被NH2、OH、NH(LA)或者N(LA)2基团所替代;
LA是具有1、2、3或4个C原子的无支链的或有支链的直链烷基,其中1、2或3个H原子可以被Hal所替代;以及
Hal是F、Cl、Br或者I。
2.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N,Y是N-R5。
3.如权利要求1的化合物,其中所述化合物选自以下组内:
5-((4-(4-(三氟甲氧基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-苯基哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-(3-氟-4-(三氟甲基)苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-(3-(三氟甲基)苯基)吡咯烷-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-(4-氯-3-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-(3-氯-4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
5-(((3R,4R)-4-(3-氯-4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
5-((4-(4-氟苯基)哌啶-3-基)氨基)喹唑啉-8-羧酰胺,
或其立体异构体或互变异构体,或者上述各物质的可药用盐。
4.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是N-R5;R5和R1一起形成具有4、5或6个环原子的单环烷基环,其中一个CH2基团被-N(L1-R6)-所替代,并且所述单环烷基环可以任选地被NH2取代。
5.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是N-R5;R5和R1一起形成具有4、5或6个环原子的单环烷基环,其中一个CH2基团被-N(L1-R6)-所替代,并且所述单环烷基环可以任选地被NH2取代;并且L1是键、-CONH-、-NHCO-、-CONHCH2-或CH2CONH-。
6.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是N-R5;R5和R1一起形成具有4、5或6个环原子的单环烷基环,其中一个CH2基团被-N(L1-R6)-所替代,并且所述单环烷基环可以任选地被NH2取代;并且R6是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、C(Hal)3O单取代、二取代或三取代。
7.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是N-R5;R5和R1一起形成具有4、5或6个环原子的单环烷基环,其中1个CH2基团可以被-N(L1-R6)-基团所替代,并且所述单环烷基环可以任选地被NH2取代;并且,L1是鍵、-CONH-、-NHCO-、-CONHCH2-或CH2CONH-;R6是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代、二取代或三取代。
8.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是NH;R1是L1-R6-L2-R7;L1和L2是键;R6是具有4、5或6个环原子的单环烷基环,其中1个CH2基团被-NH-基团所替代;R7是苯基,所述苯基可以未被取代或独立地被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代、二取代或三取代。
9.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是NH;R1是L1-R6-L2-R7;L1和L2是键;R6是哌啶基或吡咯烷基;R7是苯基,所述苯基被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代或二取代。
10.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是NH;R1是L1-R6-L2-R7;L1和L2是键;R6是R7是苯基,所述苯基被Hal、C(Hal)3、CH3、CH3O、C(Hal)3O单取代或二取代。
11.如权利要求1所述的化合物或其立体异构体或互变异构体,或者上述各物质的可药用盐,其中X是N;Y是N-R5;R5和R1一起形成具有3、4、5、6或7个环原子的单环烷基环,其中一个或两个CH2可以被-NH-、-NA-、-N(L1-R6)-、-CHA-、-CA2-、CH(L1-R6)-或-CO-基团所替代,并且所述单环烷基环任选地被NH2取代。
12.一种药物,所述药物包含至少一种如权利要求1-11中任一项所述的化合物和/或其可药用盐作为活性成分以及药学上可接受的载体。
13.一种药物组合物,所述药物组合物包含作为活性成分的如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,以及可药用载体。
14.如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,在制备用于治疗需要调节P70S6K或AKT激酶的过度增殖性疾病的药物中的用途。
15.如权利要求14所述的用途,其中所述疾病是癌症。
16.如权利要求14所述的用途,其中所述疾病是黑素瘤或卡波西肉瘤。
17.如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,在制备用于治疗需要抑制P70S6K或AKT激酶的过度增殖性疾病的药物中的用途。
18.如权利要求17所述的用途,其中所述疾病是癌症。
19.如权利要求17所述的用途,其中所述疾病是黑素瘤或卡波西肉瘤。
20.如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,在制备用于治疗需要调节P70S6K或AKT激酶的炎症、肾脏疾病、疼痛或前列腺疾病的药物中的用途。
21.如权利要求20所述的用途,其中所述炎症是胰腺炎。
22.如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,在制备用于治疗需要抑制P70S6K或AKT激酶的炎症、肾脏疾病、疼痛或前列腺疾病的药物中的用途。
23.如权利要求22所述的用途,其中所述炎症是胰腺炎。
24.一种药盒,该药盒包含下列独立包装:有效量的如权利要求1至11中任何一项所述的化合物和/或其立体异构体或互变异构体,或者上述各物质的可药用盐,以及有效量的另外的药物活性成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579377P | 2011-12-22 | 2011-12-22 | |
US61/579,377 | 2011-12-22 | ||
PCT/US2012/070085 WO2013096194A1 (en) | 2011-12-22 | 2012-12-17 | Novel heterocyclic carboxamides as modulators of kinase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104169258A CN104169258A (zh) | 2014-11-26 |
CN104169258B true CN104169258B (zh) | 2017-03-01 |
Family
ID=47459185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280063286.7A Expired - Fee Related CN104169258B (zh) | 2011-12-22 | 2012-12-17 | 用作激酶活性调节剂的新颖的杂环羧酰胺 |
Country Status (24)
Country | Link |
---|---|
US (3) | US9139568B2 (zh) |
EP (1) | EP2794571B1 (zh) |
JP (2) | JP6193880B2 (zh) |
KR (1) | KR102098358B1 (zh) |
CN (1) | CN104169258B (zh) |
AU (2) | AU2012355494B2 (zh) |
BR (1) | BR112014015327B1 (zh) |
CA (1) | CA2856448C (zh) |
DK (1) | DK2794571T3 (zh) |
EA (2) | EA027968B1 (zh) |
ES (1) | ES2614232T3 (zh) |
HK (1) | HK1201829A1 (zh) |
HR (1) | HRP20170099T1 (zh) |
HU (1) | HUE032918T2 (zh) |
IL (1) | IL233199B (zh) |
LT (1) | LT2794571T (zh) |
MX (1) | MX353062B (zh) |
PL (1) | PL2794571T3 (zh) |
PT (1) | PT2794571T (zh) |
RS (1) | RS55621B1 (zh) |
SG (2) | SG10201604799TA (zh) |
SI (1) | SI2794571T1 (zh) |
WO (1) | WO2013096194A1 (zh) |
ZA (1) | ZA201403517B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028012B1 (ru) | 2010-07-29 | 2017-09-29 | Мерк Патент Гмбх | Циклический амин-азагетероциклический карбоксамид |
SG10201604799TA (en) * | 2011-12-22 | 2016-07-28 | Merck Patent Gmbh | Novel heterocyclic carboxamides as modulators of kinase activity. |
AU2014228385B2 (en) * | 2013-03-11 | 2018-08-09 | Merck Patent Gmbh | 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
JP2021515767A (ja) | 2018-03-07 | 2021-06-24 | バイエル・アクチエンゲゼルシヤフト | Erk5阻害剤の同定及び使用 |
CN115073369A (zh) * | 2022-05-31 | 2022-09-20 | 汉瑞药业(荆门)有限公司 | 一种5-溴喹啉-8-甲醛的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308897A1 (en) * | 1987-09-24 | 1989-03-29 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1465651A (en) * | 1974-04-19 | 1977-02-23 | Wyeth John & Brother Ltd | Carbocyclic-fused ring pyridine derivatives |
JPH01156960A (ja) * | 1987-09-24 | 1989-06-20 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
TW200407324A (en) * | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
EP1615906A1 (en) | 2003-04-03 | 2006-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
MXPA06003557A (es) | 2003-09-30 | 2006-06-20 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa de proteina. |
AU2004283751B2 (en) | 2003-10-24 | 2011-05-19 | Exelixis, Inc. | p70S6 kinase modulators and method of use |
EP1687305B1 (en) | 2003-11-21 | 2008-07-09 | Novartis AG | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
BRPI0417498A (pt) | 2003-12-09 | 2007-05-29 | Us Gov Health & Human Serv | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2010093419A1 (en) * | 2009-02-11 | 2010-08-19 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
SG10201604799TA (en) * | 2011-12-22 | 2016-07-28 | Merck Patent Gmbh | Novel heterocyclic carboxamides as modulators of kinase activity. |
BR112016008378B1 (pt) * | 2013-10-14 | 2022-11-08 | Eisai R&D Management Co., Ltd | Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos |
MY192489A (en) * | 2013-10-14 | 2022-08-23 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
-
2012
- 2012-12-17 SG SG10201604799TA patent/SG10201604799TA/en unknown
- 2012-12-17 CA CA2856448A patent/CA2856448C/en active Active
- 2012-12-17 EP EP12808640.2A patent/EP2794571B1/en active Active
- 2012-12-17 CN CN201280063286.7A patent/CN104169258B/zh not_active Expired - Fee Related
- 2012-12-17 EA EA201400736A patent/EA027968B1/ru not_active IP Right Cessation
- 2012-12-17 KR KR1020147017395A patent/KR102098358B1/ko active IP Right Grant
- 2012-12-17 US US14/359,937 patent/US9139568B2/en not_active Expired - Fee Related
- 2012-12-17 LT LTEP12808640.2T patent/LT2794571T/lt unknown
- 2012-12-17 MX MX2014007364A patent/MX353062B/es active IP Right Grant
- 2012-12-17 PL PL12808640T patent/PL2794571T3/pl unknown
- 2012-12-17 ES ES12808640.2T patent/ES2614232T3/es active Active
- 2012-12-17 RS RS20170071A patent/RS55621B1/sr unknown
- 2012-12-17 AU AU2012355494A patent/AU2012355494B2/en not_active Ceased
- 2012-12-17 DK DK12808640.2T patent/DK2794571T3/en active
- 2012-12-17 HU HUE12808640A patent/HUE032918T2/hu unknown
- 2012-12-17 BR BR112014015327-2A patent/BR112014015327B1/pt not_active IP Right Cessation
- 2012-12-17 SI SI201230854A patent/SI2794571T1/sl unknown
- 2012-12-17 SG SG11201402387WA patent/SG11201402387WA/en unknown
- 2012-12-17 PT PT128086402T patent/PT2794571T/pt unknown
- 2012-12-17 JP JP2014549176A patent/JP6193880B2/ja not_active Expired - Fee Related
- 2012-12-17 WO PCT/US2012/070085 patent/WO2013096194A1/en active Application Filing
- 2012-12-17 EA EA201791073A patent/EA201791073A1/ru unknown
-
2014
- 2014-05-15 ZA ZA2014/03517A patent/ZA201403517B/en unknown
- 2014-06-17 IL IL233199A patent/IL233199B/en active IP Right Grant
-
2015
- 2015-03-06 HK HK15102308.6A patent/HK1201829A1/zh not_active IP Right Cessation
- 2015-09-08 US US14/847,561 patent/US20160058763A1/en not_active Abandoned
-
2016
- 2016-08-03 US US15/227,017 patent/US10080753B2/en active Active
-
2017
- 2017-01-20 HR HRP20170099TT patent/HRP20170099T1/hr unknown
- 2017-08-10 JP JP2017155667A patent/JP6553686B2/ja not_active Expired - Fee Related
- 2017-10-06 AU AU2017239625A patent/AU2017239625B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308897A1 (en) * | 1987-09-24 | 1989-03-29 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103930407B (zh) | 用作激酶活性调节剂的氨基嘧啶衍生物 | |
JP6616390B2 (ja) | 環式アミンアザヘテロ環式カルボキサミド | |
CN104169258B (zh) | 用作激酶活性调节剂的新颖的杂环羧酰胺 | |
CN101883774A (zh) | 噻吩并嘧啶和吡唑并嘧啶化合物及其用作mtor激酶和pi3激酶抑制剂的用途 | |
JP2022512358A (ja) | キノリン構造を有するpan-KITキナーゼ阻害剤及びその適用 | |
CN101119988B (zh) | 化学化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201829 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1201829 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170301 |
|
CF01 | Termination of patent right due to non-payment of annual fee |